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ABSTRACT
Malaria is a life-threatening disease caused by Plasmodium parasites that are spread through
the bites of infected mosquito vectors. It is a worldwide pandemic that threatens 3.4 billion people
annually. Currently, there are only a few validated Plasmodium drug targets, while drug resistance
continues to rise. This marks the urgency for the development of novel parasite-specific
therapeutics. Plasmodium falciparum diverges from the paradigm of the eukaryotic cell cycle by
undergoing multiple rounds of DNA replication and nuclear division without cytokinesis. A better
understanding of the molecular switches that coordinate the progression of the parasite through the
intraerythrocytic developmental stages will be of fundamental importance for the design of rational
intervention strategies.
To achieve this goal, we performed an isobaric tag-based approach for a system-wide
quantitative analysis of protein expression and site-specific phosphorylation events of the
Plasmodium asexual developmental cycle in the red blood cells. This study identified 2,767
proteins, 1,337 phosphoproteins, and 6,293 phosphorylation sites. Approximately 34% of identified
proteins and 75% of phosphorylation sites exhibit changes in abundance as the intraerythrocytic
cycle progresses.
Because the links between Plasmodium protein kinases as key cell cycle regulators to
cellular events are largely unknown, it is of importance to define their cognate physiological
substrates. To test the hypothesis that genetic screening would be a useful approach for discovery of
candidate substrates of a protein kinase, we used the orphan kinase PfPK7 as a model. Our
comparison of the phosphoproteome profiles between the wild-type 3D7 and PfPK7- parasites
identified 146 proteins with 239 phosphorylation sites exhibiting decreased phosphorylation in the
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absence of PfPK7 at the developmental stages where nuclear division and merozoite formation
occur. Further analysis of the decreased phosphorylated events revealed three motifs that are
enriched among phosphorylated sites in proteins that are down regulated. In vitro kinase assays
were done to validate the potential substrates of PfPK7 and to elucidate the signaling events that are
regulated by PfPK7.
In parallel to our experimental analysis, we used a computational approach for substrate
prediction from our phosphoproteome dataset. This analysis identified 43 distinct phosphorylation
motifs and a range of proline-directed potential MAPK/CDK substrates. To identify substrates/
interactors of Plasmodium CDK-like kinases, we also used HA-tagged CDK-like kinases, PfPK6
and Pfmrk lines. Co-immunoprecipitation of the HA-tagged PfPK6 and Pfmrk baits, followed by
mass spectrometric analyses, identified the components of the protein interaction complexes of
these kinases. Our analyses of HA-PfPK6 and HA-Pfmrk immunoprecipitates identified 15 and 21
proteins in the interaction complex, respectively. The ability of recombinant PfPK6 and Pfmrk to
interact and/or utilize any of the proteins identified in the interaction complex as substrates was
verified through in vitro kinase assays and pull-down analysis.
This study is the most comprehensive definition of the constitutive and regulated expression
of the Plasmodium proteome during the intraerythrocytic developmental cycle, and offered an
insight into the dynamics of phosphorylation during the asexual cycle progression [1]. In summary,
this study has 1) defined the constitutive and regulated expression of the Plasmodium proteome
during its asexual life cycle, 2) demonstrated that fluctuation and reversible phosphorylation is
important for the regulation of P. falciparum’s unique cell cycle, 3) provided the foundation for
quantitative phosphoproteomic analysis of kinase negative mutants to understand their function, 4)
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provided a major step towards defining kinase-substrate pairs operative within parasite’s signaling
networks, and 5) generated a preliminary interactome for PfPK6.
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CHAPTER 1: INTRODUCTION
1.1 Hypothesis and Specific Objectives
Regulation of the cell cycle is critical for maintaining cellular homeostasis. This is primarily
carried out by protein kinases, which act as regulatory switches in the cell cycle by phosphorylating
key proteins. Cyclin-dependent kinases (CDKs) and other protein kinases (PKs) have been shown
to be master regulators of the eukaryotic cell cycle [2] and are proven therapeutic targets for many
human diseases. Many of the Plasmodium kinases are structurally and functionally distinct from
host kinases, which would avoid potential toxicity issues [3]. Although a number of CDK-like
kinases and other PKs have been identified in Plasmodium falciparum, the molecular mechanisms
underlying the regulation of the parasite’s intraerythrocytic cell division, causing the parasite cell
cycle to deviate from the canonical eukaryotic cell cycle remain largely unknown. To decipher the
exact role of PKs in regulating malaria parasite cell growth and differentiation, it is important to
identify their specific cellular targets and their regulators. We hypothesize that global evaluation of
protein phosphorylation events of wild-type and kinase deficient mutant parasites, and
characterization of interactors and substrates of PKs will provide an understanding of the signaling
pathways that orchestrate the P. falciparum intraerythrocytic cell cycle.
To prove this hypothesis, we pursued the following specific objectives:
1) Global Analysis of Protein Expression and Phosphorylation of P. falciparum
Intraerythrocytic Developmental Stages. This specific aim investigated the dynamics
of protein expression and phosphorylation during the entire intraerythrocytic
developmental cycle of Plasmodium to reveal the constitutive versus regulated
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expression of the proteome. Furthermore, distinct phosphorylation motifs utilized by
Plasmodium kinases and potential substrates of MAPKs/CDKs were identified.
2) Phosphoproteomic Analysis of P. falciparum to Reveal Substrates of the Atypical
Kinase PfPK7. The studies in this aim are directed to better define the function of the
orphan kinase PfPK7 using a PfPK7 null cell line. In vitro kinase assays revealed the
ability of PfPK7 to directly phosphorylate three previously unknown substrates of the
kinase and aided in elucidating the role PfPK7 plays in signaling cascades.
3) Elucidating the substrates/interactors of Plasmodium CDK-like Kinases. Two
different approaches, bioinformatics and proteomic analysis of the macromolecular
complex from cell lines expressing epitope-tagged kinases, were used to define kinasesubstrate/interactor relationships of CDK-like kinases PfPK6 and Pfmrk.

1.2 Literature Review
1.2.1 Plasmodium falciparum: The Most Virulent Form of Malaria
Despite intensive efforts to eradicate or control malaria, it remains a major threat to public
health and economic development in both the tropics and subtropics. Approximately 40% of the
world’s population, over three billion people, are at risk of contracting malaria. Malaria is caused
by protozoan parasites of the genus Plasmodium in the Apicomplexan family. More than 200
species of Plasmodium have been identified that infect mammals, reptiles, or birds [4]. Four species
of Plasmodium are traditionally recognized as the causative agents of human malaria: Plasmodium
falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae [5]. Of the
Plasmodium species that infect humans, Plasmodium falciparum causes the most lethal form of
malaria, resulting in 300-600 million clinical cases and 1 to 3 million deaths annually [6].
2

Malaria infection presents a major global health challenge, currently afflicting over 500
million people worldwide and significantly increasing childhood mortality in the poorest nations,
while causing an estimated 1.3% reduction in economic productivity in affected countries [7]. The
majority of all malaria cases occur in the countries of sub-Saharan Africa. Approximately 25% of
all deaths in children under the age of five in Africa are due to malaria [8]. Outside of Africa, there
are an estimated 85 million malaria cases linked to P. falciparum infection [9]. Malaria infections
once occurred in areas such as western Europe and the United States; however, the disease has
achieved near or complete elimination due to economic development and the implantation of
improved public health policies [8]. Cases of malaria that do present in the United States or Europe
are primarily due to international travel from Africa, the Middle East, Asia, or the Amazon.
Approximately 1,500-2,000 cases of malaria are reported every year in the United States. In 2011,
1,925 cases of malaria were reported in the United States of which 58% were due to P. falciparum
infection [10]. Clinical complications resulting from P. falciparum infection include fever, anemia,
lactic acidosis, cerebral malaria, acute respiratory distress, epilepsy, hypoglycemia, and multi-organ
failures. The effect of infection in pregnant women is even more profound. When P. falciparum
infection occurs in the first or second pregnancies, the result may be spontaneous abortion, still
birth, low birth weight, and anemia or death for the mother [11].
Traditionally, there have been two avenues for the control of malaria: prevention of contact
with humans (through the removal of mosquito breeding sites, insecticides, screens, and insecticide
treated bed nets) and effective disease management (through antimalarial treatments such as
chloroquine and artemisinin combination therapies). Although antimalarials have proven useful in
the past, the extensive deployment of antimalarials has lead to selection pressure on Plasmodium
parasites, leading to the emergence of widespread resistance. While artemisinin-based combination
3

treatments (ACTs) have played an effective role in controlling the disease in many malaria endemic
areas, the appearance of parasites resistant to artemisinin derivatives in wide areas of Southeast
Asia (encompassing south Vietnam to central Myanmar) underscores the fragility of the available
malaria treatment measures [12, 13]. Therefore, there is an increased need for the identification of
novel cellular targets for therapeutic intervention. The identification of novel cellular targets
requires a nuanced understanding of the idiosyncratic molecular mechanisms that underlie
progression of the P. falciparum life cycle. Despite long-standing interest due to its medical and
biological significance, the atypical life cycle of Plasmodium remains ill defined at a molecular
level; more generally, the signaling networks that govern all aspects of its biology, from recognition
of environmental cues to cell growth and differentiation, are poorly understood [1].

1.2.2 Unique Life Cycles of Malaria Parasites
Most protozoan parasites, including many with large impacts on global public health such as
apicomplexans, have complex life cycles, which are difficult to study with classical genetic
approaches. The life cycle of the Plasmodium parasite consists of invasion from the mosquito
midgut to the human liver, and subsequent progression to human erythrocytes. The malaria parasite
life cycle, among the most complicated of any organism, is characterized by three invasive forms
(sporozoites, merozoites, and ookinetes) and several intermediary forms. The Plasmodium life cycle
consists of two asexual stages, tissue schizogony and erythrocytic schizogony, and one sexual stage
referred to as mosquito sporogony (Fig. 1) [14].
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Figure 1: The Malaria Parasite Life Cycle
Figure publically available at http://www.cdc.gov/dpdx/malaria/index.html

The lone sexual replication stage in the malaria life cycle occurs in the midgut lumen of
mosquitoes. The ookinete develops from a zygote as a direct product of fertilization between a male
and female gameotocyte. Once fertilized, the ookinete traverses the midgut epithelial layer to reach
the basal lamina, becoming immobilized and maturating into oocysts [15]. The oocysts continue to
grow and mature into sporozoites, which are released in the mosquito body and travel to the
salivary glands. When the infected mosquito bites a human host, it releases the sporozoites from the
salivary glands into the human blood stream where they are directed to the liver. In the liver, the
5

parasite invades hepatocytes and undergoes asexual replication within a parasitophorous vacuole in
a process known as exo-erythrocytic schizogony. At this stage, P. vivax and P. ovale undergo a
dormant period in which they form hypnozoites and can remain inactive up to 30 years, while P.
falciparum hepatocyte infection only last approximately 6 days. The result of this asexual
replication in the liver is a 10,000-fold amplification of parasite numbers and the release of
merozoites into the human host blood stream [16]. Free-moving merozoites attach and invade
enucleated erythrocytes where the parasite undergoes a 48-hour cycle of asexual replication and
division. During the intraerythrocytic cell cycle the parasite undergoes three morphologically
distinct stages referred to as ring (0-24 hours post infection), trophozoite (24-36 hours post
infection), and schizonts or segmenters (36-48 hours post infection). The ring stage is the earliest
intraerythrocytic stage and at this point in the cell cycle the parasite begins feeding on the newly
invaded erythrocyte. As the parasite grows, morphological changes can be seen as the ring becomes
more rounded and irregular in nature, marking the transition to the trophozoite stage. During the
trophozoite stage the parasite’s metabolism is highly active, performing glycolysis, ingesting host
cytoplasm, and performing proteolysis of hemoglobin to break it down into constituent amino acids
[8]. The transition from trophozoite to schizont stage occurs as the parasite undergoes multiple
rounds of nuclear division without cytokinesis in a process referred to as erythrocytic schizogony.
The result of schizogony is the appearance of a multinucleated schizont parasite that matures into
approximately 20 merozoites, which then rupture from the RBC and continue on to invade
uninfected RBCs [17]. In P. falciparum, P. ovale, and P. vivax the intraerythrocytic cell cycle
repeats approximately every 48 hours leading to the exponential growth of parasite numbers [8].
The intraerythrocytic stages of infection are responsible for the pathogenesis associated with
malaria. One hallmark symptom of a malaria infection is acute or severe anemia due to the
6

destruction of host erythrocytes. Other clinical complications include fever, shivering, cough,
respiratory distress, joint pain, headaches, diarrhea, vomiting and convulsions [18]. Cerebral and
placental malaria may also arise from the sequestration of mature stage parasites in the brain and
placenta. During the process of schizogony, for not well understood reasons, some of the
merozoites differentiate into sexual forms of the parasite: macrogameotocytes (female) and
microgametocytes (male), which can then be ingested by a female anopheline mosquito and
continue the sporogonic cell cycle [5].
Clearly, the intraerythrocytic cell cycle of Plasmodium is unique and complex. Accordingly,
a correlation between archetypal G1, S, G2, and M phases of eukaryotic cell cycle with those of the
Plasmodium developmental cycle is difficult to establish, and a clear understanding of the
molecular switches that coordinate DNA replication, mitosis, and cytokinesis to produce 8 to 32
merozoites from a single cell will be of great interest. The research done here focuses on using
innovative approaches to delineate P. falciparum cell cycle regulatory protein networks involving
PKs, particularly CDK-like kinases because the CDKs are master regulators that orchestrate the
activities of key proteins to precisely execute various cell cycle events [19].

1.2.3 Identification of the P. falciparum Kinome
There is a pressing need for the development of new antimalarials with novel modes of
action, such as regulators of the non-canonical cell cycle of Plasmodium. Protein kinases are an
important family of proteins that regulate diverse cellular activities. Next to G-protein-coupled
receptors, PKs are targeted heavily by the pharmaceutical industry in their screening programs.
Throughout eukaryotes, protein kinases universally function as regulatory switches to drive cell
cycle progression by phosphorylating key effector proteins, and malaria parasites are not likely to
7

be an exception. Genome-wide sequencing of P. falciparum has identified the repertoire of parasite
protein kinases (PKs) based on homology searches [20]. Surprisingly, this revealed only 65 PKs
related to eukaryotic PKs (ePKs), along with a novel ePK-related family of 20 members, named
FIKKs after a shared Phe-Ile-Lys-Lys motif in their catalytic domain [21]. This number is rather
low considering that (i) Saccharomyces cerevisiae encodes approximately twice as many ePKs
within its comparably sized genome and (ii) the parasite’s developmental cycle spans multiple
hosts, requiring specialized regulation in each. The protein sequences of the 65 identified ePKs
were used to construct a phylogenetic tree, revealing that the parasite possesses enzymes belonging
to most of the major serine/threonine kinase groups, while several of the kinases do not cluster with
any of the traditional kinase groups [21].
Based on the amino acid sequence of the catalytic domain, P. falciparum protein kinases
were classified into the major ePK serine/threonine kinase groups. There are 10 traditional ePK
kinase groups: CK1, AGC, CaMK, CMGC, TKL, STE, TyrK, RGC, PKL and Atypical. The casein
kinase 1 (CK1) family is a vast group composed of protein kinases with an acidic recognition
sequence that partake in hierarchical protein phosphorylation reactions, and phosphorylate a wide
range of substrates [22]. PfCK1 is the only malaria kinase that falls within this group [23].
The AGC group is composed of protein kinases that are directed by basic amino acids [24].
These include the cyclic nucleotide-dependent families PKA and PKG, the PKC family, the βadrenergic receptor kinase family, the ribosomal S6 kinase family, and other relatives [23]. Five
malarial kinases cluster within this group [21]. The Ca2+-calmodulin kinase (CaMK) group are also
a group of basic amino acid-directed kinases with a preference for phosphorylating serine or
threonine resides close to arginine and lysine residues [24]. The CaMK group includes protein
kinases that are regulated by Ca2+-calmodulin, calcium-dependent protein kinases (CDPKs), the
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SNF1/AMP-activated kinase family, and other relatives [23]. To date, 13 P. falciparum kinases
have been identified in this group, which demonstrates the significance of calcium signaling in the
malaria parasite [25].
The tyrosine-like kinases (TKL) are a group of serine/threonine protein kinases with close
sequence similarity to tyrosine kinases. Five malarial kinases show homology to the TKL group;
however, their ability to function as a TKL kinase has yet to be shown [21]. No malarial protein
kinases have been identified that cluster with the STE, TyrK, RGC, or PKL groups [23]. The STE
group of kinases are homologs of the yeast STE7, STE11, and STE20 genes, which form the
MAPK cascade and act in a signal transduction pathway. Unlike traditional protein kinases that
phosphorylate serine or threonine residues, members of the tyrosine kinase (TyrK) group almost
exclusively phosphorylate tyrosine residues. The RGC is a small group consisting of receptor
guanylate cyclases, while the PKL group is a larger group sharing a PKL fold and catalytic
mechanism. Although no malaria protein kinases cluster with the STE, TyrK, RGC, or PKL groups,
several do not clearly cluster with any defined group and are classified as “orphan” kinases. This
group does not strongly associate with any established ePK group [26].
The most prominent group in the Plasmodium kinome is the CMGC group. Eighteen
malarial kinases cluster in this group. The CMGC group are frequently proline-directed protein
kinases and include the family of cyclin-dependent protein kinases (CDKs), mitogen-activated
protein kinases (MAPKs), glycogen-synthase kinase 3 family, CDK-like kinases (CLK), and other
close relatives [23]. MAPK pathways play crucial roles in the control of eukaryotic cell
proliferation in response to various extra- or intracellular stimuli [27]. In eukaryotic systems, the
majority of the CMGC kinases are involved in the control of cell proliferation and development,
highlighting the significance of kinases belonging to this cluster. Kinases belonging to either ePKs
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or “orphan” kinase groups are fitting potential drug targets due to their predicted roles in regulating
the unique P. falciparum life cycle and due to the distinct structural and functional characteristics
they possess in comparison to their human host which may provide P. falciparum-specific targets
[28, 29].

1.2.3.1 Cyclin-dependent Protein Kinases
Cyclin-dependent kinases (CDKs) are a large group of proteins that have a critical role in
cellular processes such as cell cycle progression, transcription, DNA replication and repair,
apoptosis, and differentiation. Abnormalities in the regulation of CDKs lead to numerous cell cycle
defects and a wide variety of diseases. Currently, CDKs are being investigated as potential drug
targets in cancer, neurological disorders, and cardiovascular disease [30]. Due to their highly
conserved nature and their role in cell growth, CDKs are attractive targets for therapeutic
intervention. In it’s active form, CDKs are heterodimers consisting of a catalytic serine/threonine
kinase subunit and a regulatory subunit. When an inactive CDK binds its cognate cyclin it becomes
a partially active enzyme and there is a displacement of a sterically hindering “T-loop” exposing
critical residues in the catalytic cleft [31]. CDKs will then become fully active when a CDK
activating complex (CAK) phosphorylates a conserved threonine residue within the “T-loop” of the
CDK [32]. The CAK complex traditionally is composed of CDK7, cyclin H, and the stabilizing
partner MAT1 [2]. Several CDKs and cyclins have been identified in P. falciparum by using
homology-based PCR and database mining [33]. Although CDKs and cyclins have been identified
in P. falciparum, the regulatory mechanisms responsible for activating and inhibiting CDK activity
in Plasmodium remain unknown. Furthermore, the substrates of CDKs and CDK regulation
mechanisms of the non-canonical malarial cell cycle have yet to be determined.
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In P. falciparum, 6 CDK-related protein kinases have been identified, PfPK5, PfPK6,
Pfmrk, Pfcrk-1, Pfcrk-3, Pfcrk-4 [19]. PfPK5, a putative homologue of p34cdc2 cyclin-dependent
kinase required for both entry into S-phase and mitosis in fission yeast, was the first CDK-like
kinase characterized in P. falciparum with 60% identity to human cdc2 [34]. PfPK5 co-localizes
with the nuclear stain at the onset of schizogony [35]. It possesses a fairly conserved cyclin binding
PSTAIRE motif (PSTTIRE) and potential sites of regulatory phosphorylation (equivalent to Thr14,
Tyr15, and Thr160 of CDK2). The structure of PfPK5 has been determined recently to a resolution
of 1.9Å [36]. PfPK5 has structural homology to human CDK2, the only other monomeric CDK
structure solved.

1.2.4 P. falciparum Protein Kinase 6
Plasmodium falciparum protein kinase 6 (PfPK6) is a novel protein kinase that has sequence
homology to mitogen activated protein kinases (MAPKs) and also to cyclin dependent kinases
(CDKs). Both MAPKs and CDKs have important functions in the regulation of growth and cell
cycle in eukaryotes. PfPK6 shows some structural and functional resemblances to eukaryotic
CDKs. The similarity of the catalytic domain of PfPK6 to CDK2 and MAPK is 57.3% and 49.6%,
respectively [37]. Another feature suggesting PfPK6 functions as a CDK-like kinase is the presence
of conserved regulatory phosphorylation sites found in other CDKs: Thr14, Thr15, and Thr160 in
CDK2 [19].
Although PfPK6 shows sequence homology to CDKs, there are several lines of evidence
suggesting that PfPK6 is a cyclin-independent kinase. First, the recombinant PfPK6 shows
significant auto-phosphorylation and phosphorylation of the control substrate histone in the absence
of a cyclin. Secondly, PfPK6 activity is not stimulated by incubation with cyclins [19]. Thirdly,
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several amino acids in the N-terminal lobe of CDKs that are involved in cyclin binding are absent
from PfPK6. Furthermore, closer examination of the canonical cyclin binding PSTAIRE motif in
CDKs reveals that the motif is replaced by a SKCILRE sequence in PfPK6 [37]. These observations
suggest that PfPK6 is not a traditional CDK and instead is a unique “cyclin-independent” CDK that
may be regulated through its own synthesis or degradation and not the binding of a cyclin partner
[19].
PfPK6 transcript levels were found to peak at the trophozoite stage, the cell cycle stage
thought to correspond to the onset of the classical S phase during which DNA replication occurs
[37]. Protein expression levels of PfPK6 were detected at both the trophozoite and schizont stages,
with peak expression occurring at the trophozoite stage. Previous in vitro kinase assays detected the
ability of PfPK6 to auto-phosphorylate, phosphorylate histone, and phosphorylate the small subunit
of the malarial ribonucleotide reductase. It was also shown that PfPK6 activity is sensitive to
common CDK inhibitors such as roscovitine [37]. Identifying and characterizing substrates and
interactors of PfPK6 will generate a preliminary network of interactions for PfPK6 and provide
insight into its function(s) in Plasmodium signaling networks.

1.2.5 P. falciparum MO15-related Protein Kinase Pfmrk
Pfmrk was first isolated in 1997 through a PCR approach. Homology searches of Pfmrk
revealed that it has the highest sequence identity (46%) to human CDK7 of all of the mammalian
CDKs [38]. CDK7 has a dual function as the TFIIH associated kinase responsible for regulation of
transcription and DNA repair and activates down-stream CDKs through “T-loop” phosphorylation
[39]. As part of the CAK complex, CDK7 traditionally binds cyclin H and the stabilizing partner
MAT1. Previous studies have shown the ability of Pfmrk to phosphorylate both histone H1 and the
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carboxyl-terminal domain of the large subunit of RNA polymerase II [40, 41]. Furthermore, Pfmrk
activity was stimulated in vitro when it was associated with human cyclin H (the cyclin partner of
human CDK7) or Pfcyc-1 (a cyclin homolog in P. falciparum) [40, 42]. Although in vitro studies
support the notion that Pfmrk is a Plasmodium CDK homologue, more recent studies suggest that
Pfmrk may be a member of a unique protein kinase family [43]. To date, Pfmrk has not been shown
to possess CAK activity against PfPK5 or other CDK-related kinases; however, Pfmrk has been
shown to interact and co-localize with the C-terminal domain of PfMAT1 [31, 42]. Previous
studies also showed the interaction of Pfmrk with two DNA replication proteins, PfRFC-5 and
PfMCM6 and the ability of Pfmrk to utilize these proteins as substrates. Taken together, the data
suggest a role for Pfmrk in the nucleus of the parasite presumably in regulation of the DNA
replication machinery, rendering it a highly attractive target for therapeutic inhibitors [31].

1.2.6 P. falciparum Atypical Protein Kinase 7
Plasmodium falciparum protein kinase 7 (PfPK7) is one possible P. falciparum-specific
target with no human homolog [21]. PfPK7 is an “orphan” kinase displaying regions of homology
to more than one protein kinase family. The C-terminal lobe of PfPK7 displays maximal homology
to the MEK family, while the N-terminal lobe is related to the fungal cyclin AMP-dependent
kinases [27]. Sequence analysis revealed the two closest human homologs as dual specificity
mitogen activated protein kinase 3 (MAP2K3) and serine/threonine-protein kinase 6 (Aurora-A)
with 33% and 26% sequence homology, respectively [44]. Previous studies have demonstrated the
in vitro kinase activity of PfPK7 to autophosphorylate and phosphorylate a number of substrates
including myelin basic protein, histone H2A, and β-casein [45]. Despite possessing homology to the
MEK family of kinases, PfPK7 was not able to phosphorylate MAPK homologs and was not
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inhibited by MEK inhibitors; therefore, PfPK7 is not likely to function as a MEK homolog in P.
falciparum [45].
PfPK7 has been shown to be expressed at both the asexual and sexual stages of the human
host, as well as within the mosquito. Through the use of reverse genetics, Dorin-Semblat et al.
disrupted the PfPK7 gene, which resulted in the slowing down of parasite growth through a
reduction in the number of merozoites produced by each schizont and through a reduction in the
ability to produce oocysts in the mosquito [27]. This observed phenotype suggests that PfPK7 is
involved in parasite proliferation and development, marking PfPK7 as a promising Plasmodiumspecific drug target.

1.2.7 Current Technologies used to Identify Protein Kinase Substrates
Protein kinases are the largest group of enzymes capable of post-translational modifications
in eukaryotes [46]. Protein kinases are responsible for phosphorylating protein substrates by
transferring a phosphate group from adenosine-triphosphate (ATP) to a serine, threonine, or
tyrosine residue on the substrate protein [47]. This essential post-translational modification
regulates nearly every aspect of biological pathways, from protein-protein interactions to signal
transduction [48]. When protein phosphorylation becomes deregulated, it often leads to the
development of numerous diseases such as cancer. Therefore, phosphorylation analysis to identify
phosphorylated proteins and quantitative changes in phosphorylation is crucial to understanding
how signaling networks function and how the disruption of these networks lead to disease states.
There are five traditional approaches used when investigating phosphorylation events:
genetic screening, in vitro kinase assays, protein interaction-based substrate screening, mass
spectrometry-based high throughput screening, and bioinformatics of kinase-substrate predictions
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[46]. Genetic screening is one of the most historically applied approaches used to discover potential
substrates of protein kinases. Once the phenotype of a particular kinase knockout has been
determined, high throughput genetic manipulation is performed, such as siRNA, on a genome-wide
scale in order to screen all the genes that can mimic the kinase knockout phenotype. The genes
capable of producing a similar phenotype are then tested to determine if they are true substrates of
the kinase being investigated [46]. This approach has been successful in model organisms such as
yeast, worms, and flies where genetic manipulation can be conducted easily; however, this
approach is not as feasible for nontraditional organisms such as Plasmodium.
Another approach to identifying protein kinase substrates is in vitro kinase assays. This is
the most commonly used method when determining kinase activity toward substrates. This
technique is performed by incubating a purified kinase with a purified putative substrate in the
presence of ATP. The ability of the kinase to utilize any given substrate is then assessed through
colorimetric, radioactive, chemiluminescent, or fluorometric techniques [49]. Perhaps the biggest
limitation to this approach is the fact that in vitro phosphorylation may differ from true
physiological events. Another limitation is the fact that a researcher must have an idea of what
proteins are being phosphorylated by a particular kinase, which is why in vitro kinase assays are
typically used as a confirmatory technique to verify previously identified substrates.
More recently, focus has been placed on the use of protein interaction-based substrate
screening in order to identify kinase-interacting proteins. A number of approaches have been used
to study protein-protein interactions in order to identify potential kinase substrates; however,
phosphorylation is usually a transient protein-protein interaction, making the detection of substrates
through protein-protein interactions difficult [46]. The use of mass spectrometry-based high
throughput screening and bioinformatics of kinase-substrate predictions have recently become
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widely used due to the advancements in technology in the past decade. These techniques are
discussed in detail within the following two sections.

1.2.8 Quantitative Mass Spectrometry in Proteomics
Traditional proteomic quantification approaches utilize dyes, fluorophores, or radioisotopes
to determine the relative abundance of a protein in a particular sample. The advantages associated
with the classical methods include good sensitivity and range, but they require high-resolution
protein separation and do not lead to the identification of the protein, demonstrating the need for
modified techniques [50]. In recent years, the field of proteomics has grown vastly with an
emphasis placed on the development of techniques that allow for the comparison of protein
abundance among biological samples. This quantitative comparison allows for the characterization
of changes in protein abundance in various organisms under many different biological conditions.
The most successful strategies currently in use rely on the introduction of an isotope-coded tag,
which is used to differentiate among samples. In 1999 3 different laboratories reported the first
usage of stable isotope labeling which has become a staple of the proteomics field since then [5153]. Currently, there are a variety of approaches used to introduce the isotope tags including
metabolically, chemically, or enzymatically; however, once the tags have been incorporated, the
fundamental strategy for each technique is the same. More specifically, after tag incorporation, the
samples are combined and analyzed simultaneously in order to reduce experimental error between
samples [54]. Next the intensities of the different isotope tags can be compared in order to
determine the relative abundance of each peptide, which can then be used to infer the relative
abundance of each parent protein [54].
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Metabolic labeling is the first point possible for introducing a stable isotope tag into
proteins, which occurs during cell growth and division. The first use of metabolic labeling was
performed using 15N-enriched cell culture medium for total labeling of bacteria [52]. The technique
has since expanded and been used in a wide range of organisms. One of the most widely used
approaches for metabolic labeling is the stable isotope labeling by amino acids in cell culture
(SILAC) method, which was first introduced in 2002 [55]. This method utilizes a culture medium
containing 13C6-arginine and 13C6-lysine in order to ensure that all tryptic peptide products carry at
least one labeled amino acid. Proteins are identified on the basis of fragmentation spectra from one
“heavy” and one “light” peptide and subsequently the relative quantification was determined based
on the comparison of the intensities of isotopes [50]. The utility of metabolic labeling comes from
the fact that samples treated differently can be pooled for analysis, which reduces the amount of
introduced experimental error during protein extraction, protein digestion and fractionation. One of
the biggest limitations of metabolic labeling is the small varieties of labels are available for use. For
example, SILAC labeling can only use two labels, which restricts the number of conditions that can
be compared in one experiment to three (two labeled and one unlabeled). Overall, metabolic
labeling is one of the most accurate quantitative MS methods when comparing a small number of
conditions due to the early combination of samples [50].
Chemical or enzymatic incorporation of isotope tags is performed in vitro as a postbiosynthetic mechanism. Enzymatic labeling is usually performed after proteolytic digestion and
was traditionally labeled by the integration of 18O into the COOH-termini of peptides [56]. When
using this method, it is rare that complete labeling could be achieved; therefore, the rate of
incorporation of labels into individual peptides vary enormously, making accurate analysis of data
more complicated [57]. In 1999 a novel approach was created utilizing an affinity-tag that is
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isotope-coded (ICAT) that specifically labels cysteine residues with zero or eight deuterium atoms
as well as a biotin group. A disadvantage to this approach is the fact that there are a significant
number of proteins that contain few to no cysteine residues and therefore will not be labeled [51].
Another method of protein and peptide labeling utilizes labeling reagents that target the
peptide N-terminus and the epsilon-amino group of lysine residues [50]. The isotope-coded protein
label (ICPL), isotope tags for relative and absolute quantification (iTRAQ), and tandem mass tags
(TMT) are among the tags capable of this type of labeling. When using a protein or peptide tag,
relative quantification is accomplished using the integration of mass spectrometric signals
originating from “heavy” and “light” labeled peptides [50]. However, the concept of isobaric mass
tagging is divergent from the above concept by attaching tags that generates isobaric labeled
peptides which co-migrate in chromatographic separations. Once fragmentation of peptides has
been performed, the different tags can then be identified from the MS data. Thus this approach
enables us to determine simultaneously the identity as well as the relative abundance of pair of
peptides resulting from tandem mass spectra, which is a great advantage. Another advantage of this
approach is the commercial availability of iTRAQ reagents allowing for multiplexed quantification
of up to eight samples and the comparison of up to eight time points or treatments in the same
experiment [58].
In order to determine the absolute quantification of proteins, an isotope-labeled synthetic
internal standard must be used. This is attained by the introduction of a known amounts of a
standard peptides that are stable isotope-labeled to the digested protein followed by the comparison
of the signals from MS to the experimental sample peptides [59]. More recently, synthetic genes
have been constructed that, upon digestion with trypsin yield peptides of the same protein to be uses
as a standard for quantification. This approach increases confidence in the quantification process
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and removes experimental bias that could occur during the digest process [60]. Although the
introduction of an internal standard greatly enhances sample quantification, sample quantification is
limited by the co-elution of peptides with a similar mass. This limitation is overcome by decreasing
sample complexity by introducing biochemical fractionation prior to LC-MS analysis [50]. The
general procedure for obtaining information from MS and MS/MS spectra that is quantitative is
similar among different quantification approaches. Figure 3 depicts in yellow the quantification
steps that are common between approaches with and without utilizing stable isotopes, while the
blue boxes illustrate the additional steps that are required when the MS signal intensity values are
used for quantification [50].

Figure 2: Quantitative Mass Spectrometry Data Processing and Analysis Workflow
Figure adapted from [50]
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Spectra counting is most frequently used when determining relative protein quantification
between multiple samples. For this analysis, the number of spectra observed for a protein in each
condition is counted and compared among the different conditions in order to determine if there is a
significant difference. This method can lead to variation among experiments due to varying levels
of peptide detection. In order to diminish this effect, most quantitative proteomic studies average
the ratio of spectra between experiments; however, this approach can also vary based on signal
intensity [61]. Protein quantification can be improved by either calculating a weighted average of
intensities, addition up all measured quantities, and by calculating the ratio of proteins, or by
computing a linear regression to determine the protein ratio [61-63].
Quantitative mass spectrometry is most frequently used to correlate a protein’s abundance in
an experimental condition or to determine the protein interactions. The most common use of
quantitative mass spectrometry is to detect protein abundance changes among experimental
conditions. This method has recently been applied as a comprehensive investigative tool of
biological phenomena, as was performed in this study to define the constitutive and regulated
expression of the proteome during the intraerythrocytic developmental cycle.

1.2.9 Phosphoproteomic Analysis
Protein phosphorylation is One of the post-translational modifications (PTMs) in living cells
that is of major significance in protein phosphorylation. This is because the reversible protein
phosphorylation has a central regulatory role in signal transduction mechanisms across species.
Protein phosphorylation is involved in a diverse regulatory processes such as regulation of cell
cycle, transmission of signals from cell surface to the nucleus, cellular differentiation, normal and
aberrant cell proliferation, and metabolic processes [64]. Protein kinases and phosphatases account
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for 2-4% of eukaryotic proteomes and are responsible for controlling substrate modifications
through reversible phosphorylation and dephosphorylation [65, 66]. Protein phosphorylation plays a
crucial role in the cell and it is estimated that about 30% of all eukaryotic proteins are reversibly
phosphorylated. The level of phosphorylation in an individual protein ranges from less than 1% to
greater than 90% [67, 68]. Protein phosphorylation acts as a regulatory mechanism in signal
transduction pathways by activating or deactivating key proteins. A disruption in the balanced
control of protein phosphorylation has been linked to many diseases, including cancer [48, 69].
Protein phosphorylation can be discovered and visualized in SDS PAGE gels of proteins
that are 32P labeled proteins or by western blot analysis with phospho-specific antibodies. Although
these approaches are limited in their ability to identify novel phosphoproteins or to localize
phosphorylation sites within a protein [64]. Mass spectrometry has evolved drastically in recent
years and can now identify, localize, and quantify thousands of in vivo phosphorylation sites. It can
also be applied in studies examining almost any question in basic cell biology in a wide variety of
biological contexts. Mass spectrometry based phosphoproteomics is frequently used to delineate
cell signaling pathways. More specifically, the relative quantification of signaling molecules
involved in various signaling cascades as well as their phosphorylation sites can be determined
[64]. Phosphoproteome analysis has been performed in many organisms ranging from yeast to
mouse and has proven to be an important tool for defining key proteins within cellular signaling
networks.
Phosphoproteomic analysis is frequently used to study whole-tissue physiology, cell
differentiation status, signal transduction cascades, and kinase/substrate specificity. The preferred
method in quantitative mass spectrometric based proteomic analysis utilizes the enzymatic
digestion of complex samples into peptide mixtures that are resolved by liquid chromatography
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followed by MS analysis [64]. Sample preparation for phosphoproteomic analysis is similar to
quantitative proteomic sample preparation; except that phosphopeptides, representing only a small
percentage of total peptides present in a total lysate sample, needs to be enriched for efficient
detection by mass spectrometry. There are many methods currently being used to enrich total lysate
samples for phosphopeptides, the most common are affinity and antibody-based methods. The
typical workflow used for quantitative phosphoproteomics is depicted in Fig. 4 [64].
One of the most common phosphopeptide enrichment strategies being used today is
immobilized metal affinity chromatography (IMAC). IMAC is based on the concept that covalent
bonds form between specific amino acids, such as histidine and cysteine, and metal ions. Proteins
with an affinity for metal ions will be retained in a column containing immobilized metal ions, such
as cobalt, nickel, copper, iron, zinc, aluminum, or gallium. Iron, aluminum, and gallium are the
preferred ions for phosphopeptide enrichment and are typically immobilized to iminodiacetic acid
(IDA) derived resin [70]. The IMAC concept was first introduced by Anderson et al in 1986 [71]
and later improved upon by Tempst et al who compared the selectivity of a variety of metals in the
IMAC procedure and their ability to bind phosphopeptides [72]. During the optimization process,
Tempst et al observed the best selectivity with IDA columns complexed with gallium in the pH
range of 2.0-3.5 [72].
Another approach used for the enrichment of phosphorylated peptides is strong cation
exchange chromatography (SCX). This method is based on the concept that phosphorylated and
non-phosphorylated peptides are going to have a difference in the solution charge states. More
specifically, at a pH of 2.7, the negatively charged phosphate group on a phosphorylated peptide
causes a decrease in net charge, which allows for their enrichment over non-phosphorylated
peptides [64]. Although this technique is useful, it does not allow for multi-phosphorylated peptides
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to be bound to the SCX column due to their net zero charge, which is why SCX is typically a first
step in the phosphopeptide enrichment workflow and is usually followed by IMAC. The
combination of SCX and IMAC is a strong analytical tool used in many large-scale
phosphoproteomic studies [73-75].

Figure 3: Typical Quantitative Phosphoproteomics Workflow
Figure publically available at https://www.biochem.mpg.de/225898/Phosphorylation
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Global phosphoproteomic studies based on mass spectrometry have generated qualitative
and quantitative data describing protein phosphorylation events in various biological systems.
Reversible phosphorylation of proteins regulates many cellular processes. Activation of most
signaling pathways in eukaryotes is because of coordinated phosphorylation events across many
proteins over time. The malaria parasite life cycle is complex and the regulation of proliferation and
differentiation events by protein phosphorylation is likely a crucial aspect. The divergence between
human and malarial protein kinases suggest that specific inhibition of malarial protein kinases is
feasible.

1.2.10 The P. falciparum Proteome and Phosphoproteome
Despite long-standing interest due to its medical and biological significance, the atypical life
cycle of Plasmodium remains ill defined at a molecular level. The signaling networks that govern
all aspects of the parasite’s biology, from recognition of environmental cues to cell growth and
differentiation, are poorly understood. To date, our knowledge of this organism has been restricted
due to challenges in applying traditional biochemical, cell biological, and genetic screens in this
system. However, in recent years, a variety of technological advances have enabled a paradigm shift
in biology, broadening the focus from studies restricted to individual genes or proteins to a systemwide, global analysis of cellular networks. Importantly, many of these technologies, including mass
spectrometry-based methods for global quantitative analysis of proteomes and phosphoproteomes,
have proven to be applicable to Plasmodium, thus offering unprecedented insights into the
molecular foundations of this organism’s unique and medically important life cycle [76-78].
A variety of previous proteomic studies utilizing a wide range of technologies for
fractionation and quantification have explored various stages of the Plasmodium life cycle [79-82].
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These studies have investigated sporozoite, merozoite, trophozoite, schizont, and gametocyte stages
independently of one another and typically identified several hundred to approximately 2,500
proteins [81-85]. Multidimensional protein identification (MudPIT) technology was used for a
system-wide comparison of the transcriptome and proteome; however, this study detected proteins
from only 50% of the transcripts in the asexual stages [79]. Significantly, this study revealed a
delay in the appearance of proteins compared to that of the transcripts, indicative of a major role of
post-transcriptional mechanisms in the regulation of gene expression. Profiling of schizont stage
protein expression by two-dimensional differential gel electrophoresis followed by mass
spectrometric analysis provides evidence for post-transcriptional regulation of gene expression [80].
Recently, merozoite proteome analysis using isobaric tagging and strong cation exchange (SCX)
fractionation found 677 proteins of which 92 are post-transcriptionally regulated [81]. Another
study using MudPIT identified 802 proteins in the P. falciparum nuclear proteome [82].
Phosphoproteome analysis has been performed in many organisms ranging from yeast to
mouse in order to profile the phosphorylation status of the proteome. By providing a global
overview of phosphorylation, these studies have proven to be important tools for defining key
proteins within cellular signaling networks. An initial attempt to profile schizont stage protein
expression was performed with two-dimensional differential gel electrophoresis followed by mass
spectrometric analysis and identified 170 proteins [86]. More recently, reports describing the
characterization of the P. falciparum phosphoproteome focused on the schizont stage of the
intraerythrocytic growth of the parasite. The first study used immobilized metal ion affinity (IMAC)
and TiO2 chromatography followed by LC-MS/MS analysis to identify 650 proteins with 1,177
phosphorylation sites [77]. Another study used SCX chromatography, IMAC, and LC-MS/MS to
detect 1,673 proteins that are phosphorylated at 8,463 sites [76]. A third study used two sample
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preparation procedures (i) SDS-PAGE protein gel fractionation and phosphopeptide enrichment
with TiO2 followed by LC-MS/MS and (ii) filter assisted sample preparation (FASP) with strong
anion exchange chromatography followed by TiO2 phosphopeptide enrichment and LC-MS/MS to
identify 929 proteins with 2,541 phosphorylation sites [78]. Nonetheless, these earlier studies have
examined only mature schizont stage parasites. Notably, these previous studies did not investigate
the dynamics of protein expression and phosphorylation during the entire intraerythrocytic
developmental cycle of Plasmodium. Here we present a comprehensive analysis of protein
expression and phosphorylation across the three major developmental stages in the P. falciparum
intraerythrocytic asexual cycle using isobaric labeling [58, 87]. This comparative analysis revealed
stage-specific profiles of protein expression and phosphorylation.
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CHAPTER 2: GLOBAL ANALYSIS OF PROTEIN EXPRESSION AND
PHOSPHORYLATION OF THREE STAGES OF PLAMSODIUM
FALCIPARUM INTRAERYTHROCYTIC DEVELOPMENT
Reproduced with permission from Pease, B.B., et. al., Global Analysis of Protein Expression and
Phosphorylation of Three Stages of Plasmodium falciparum intraerythrocytic Development. Journal
of Proteome Research, 2013. 12(9): p. 4028-4045.

2.1 Summary
During asexual intraerythrocytic development, Plasmodium falciparum diverges from the
paradigm of eukaryotic cell cycles by undergoing multiple rounds of DNA replication and nuclear
division without cytokinesis. A better understanding of the molecular switches that coordinate the
numerous events governing the progression of the parasite through the intraerythrocytic
developmental stages will be of fundamental importance for rational design of intervention
strategies. To achieve this goal, we performed isobaric tag-based quantitative proteomics and
phosphoproteomics analyses of three developmental stages in the Plasmodium asexual cycle and
identified 2,767 proteins, 1,337 phosphoproteins, and 6,293 phosphorylation sties. Approximately
34% of identified proteins and 75% of phosphorylation sites exhibit changes in abundance as the
intraerythrocytic cycle progresses. Our study identified 43 distinct phosphorylation motifs and a
range of potential MAPK/CDK substrates. Further analysis of phosphorylated kinases identified 30
protein kinases with 126 phosphorylation sites within the kinase domain or in N- or C-terminal
tails. Many of these phosphorylation events are likely CK2-mediated. We defined the constitutive
and regulated expression of the Plasmodium proteome during the intraerythrocytic developmental
cycle, offering an insight into the dynamics of phosphorylation during asexual cycle progression.
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Our system-wide comprehensive analysis is a major step toward defining kinase-substrate pairs
operative in various signaling networks in the parasite.

2.2 Materials and Methods
2.2.1 Plasmodium falciparum Culture
Parasites of Plasmodium falciparum strain 3D7 were initially grown at a 4-10% parastemia
and 4% hematocrit in RPMI 1640 culture medium supplemented with A+ erythrocytes and 5%
Albumax as previously described [88]. Schizont stage parasites were magnetically synchronized as
described by Kim et al. using a MACS LD (Miltenyi Biotec Auburn, CA) column with a MidiMACS Separator [89, 90]. Parasite-infected erythrocytes were added to a fresh culture plate and
supplemented with A+ blood and fresh medium to adjust to a 4% hematocrit.
Approximately 7-8 hours after MACS synchronization, the parasites had re-infected and
entered the ring stage. At this point, parasites were re-synchronized by treatment with 5% sorbitol
(w/v). Parasite growth and parastemia were monitored by evaluating Giemsa-stained blood smears
under the microscope. Tightly synchronized ring (approximately 16 hours ± 4 hours post-invasion),
trophozoites (approximately 26 hours ± 4 hours post-invasion), and schizonts (approximately 36
hours ± 4 hours post-invasion) were harvested following established protocols [91]. Parasites were
isolated by lysing the red blood cells in 0.1% saponin followed by thorough washing in PBS. The
subsequent pellets were weighed and proteins were immediately extracted by lysis in an 8M urea
lysis buffer supplemented with protease and phosphatase inhibitors (8M urea, 75mM Tris, pH 8.2,
1X HALT protease inhibitor, 1X HALT phosphatase inhibitor) [92]. Lysates were cleared by
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centrifugation for 10 minutes at 4°C at 14,000 rpm. Protein concentration was determined for each
sample by BioRd Bradford Assay. Duplicate samples were prepared for each developmental stage.

2.2.2 Sample Preparation and Mass Spectrometry
Equal quantities of duplicate protein extracts (1mg) from each of the three intraerythrocytic
P. falciparum stages were reduced, alkylated, and digested with Lys-C prior to labeling with one of
6 TMT isobaric labeling reagents [87]. All 6 samples were then mixed together and separated via
strong cation exchange chromatography and a total of 20 fractions were collected. Each of the 20
fractions was then analyzed via LC-MS/MS on an LTQ-Orbitrap-Velos mass spectrometer
essentially as described previously [93] except that high-resolution MS/MS spectra were acquired
for all precursors and used for both identification and quantification. Individual peptides were
identified using Sequest [94] and proteins were filtered to a false discovery rate (FDR) of 1% as
described previously [95]. Database searches employed a composite database containing
Plasmodium falciparum sequences obtained from NCBI [96] as well as human protein sequences
derived from the International Protein Index [97] and common contaminants such as Lys-C; all
sequences were included in forward and reverse orientations. For quantification, peptides matching
each protein were grouped and their MS2 TMT reporter ion intensities were scaled to a sum of 1.0.
An ANOVA model was used to identify differentially expressed proteins based on the
quantification of individual peptides. The Benjamini-Hochberg approach was used to correct for
multiple hypothesis testing.
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2.2.3 Phosphopeptide Enrichment and Identification
Following protein extraction, samples containing 1mg of protein per stage were reduced,
alkylated and digested with Lys-C and subequently labeled with one of 6 TMT isobaric labeling
reagents. The resulting peptides were fractionated via SCX (strong cation exchange
chromatography). The resulting 20 fractions were subjected to immobilized metal affinity
chromatography (IMAC) to specifically pull out phosphorylated peptides [92]. Phosphopeptides
were analyzed via LC-MS/MS on an LTQ-Orbitrap mass spectrometer essentially as described
previously [93], except that all MS/MS spectra were acquired at high resolution in the Orbitrap and
used for both phosphopeptide identification and quantification. Peptides were identified by
matching individual MS/MS spectra with peptide sequences using Sequest [94]. As before, searches
employed a database containing Plasmodium sequences from NCBI [96] as well as human protein
sequences from IPI [97]. The peptides were filtered using a multivariate approach to remove
questionable identifications based on a target-decoy strategy [95, 98]. Peptides were assembled into
proteins and proteins were further filtered to ensure a protein-level false discovery rate of 1%.
Individual phosphorylation sites on each peptide were scored to assess how confidently the
modification could be localized to a single residue using AScore [99]. Finally, the peptides and
proteins were filtered to account for protein redundancy.
For quantification, TMT reporter ion signals were extracted from MS/MS spectra and
normalized assuming equal protein loading in each channel. Each phosphorylation site was
quantified by gathering together all matching peptides, filtering out peptides that didn’t meet the
quantification standards, and re-scaling reporter ion intensities so that they summed to 1.0.

30

2.2.4 Western Blotting with Phospho-Specific Antibodies
Plasmodium falciparum 3D7 strain parasites were grown as described above. Ring stage
parasites were synchronized by treatment with 5% sorbitol (w/v). Parasite growth and parastemia
were monitored for a 48-hour recovery period. After the parasites progressed through an entire
intraerythrocytic cell cycle, parasites were harvested every 8 hours for 48 hours following
established protocols [91]. Parasites were isolated by lysing the red blood cells in 0.1% saponin
(w/v), followed by thorough washing in PBS. The subsequent pellets were weighed and recorded.
Proteins were immediately extracted by lysis in an 8M urea lysis buffer as described above and
centrifuged for 10 minutes at 4°C at 14,000 rpm. A BioRad Bradford Assay was used to determine
the protein concentrations of the cleared lysates. The protein lysates were then stored at -80°C until
use.
For Western blotting, 100μg of protein extract from each time point were loaded on a
NuPAGE 4-12% Bis-Tris gel with NuPAGE MOPS SDS Running Buffer and run at 100 volts for
approximately 3 hours following the manufacturer’s instructions (Invitrogen). After electrophoresis,
the gels were rinsed in transfer buffer (NuPAGE 1X Transfer Buffer) and transferred onto
nitrocellulose using the NuPAGE wet transfer module at 30 volts for 1 hour at 4°C according to the
manufacturer’s instructions (Invitrogen). The membranes were blocked in 5% BSA in tris-buffered
saline containing 0.1% Tween 20 for 1 hour at room temperature. The membranes were then
incubated with the relevant antibody from Cell Signaling Technology (Phospho-Tyrosine Mouse
mAb (P-Tyr-100) #9411 1:2000 and Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2)
Rabbit mAb #2325 1:1000) overnight in 5% BSA tris-buffered saline containing 0.1% Tween 20 at
4°C following the suggested dilutions. The membranes were washed, incubated with horseradish
peroxidase-conjugated secondary antibody at a 1:2000 dilution for 1.5 hours at room temperature,
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washed, and developed using enhanced chemiluminescence detection according to the
manufacturer’s instructions (Cell BioSciences).

2.2.5 Immunoprecipitation with PTMScan Direct
The PTMScan Direct protocol is adapted from the PhosphoScan® method developed at Cell
Signaling Technolgy with licensed use [100].
Cell Lysate Preparation- Parasite extracts were prepared as described above. The protein
pellets were lysed in urea lysis buffer (20mM HEPES, pH 8.0, 9M urea, 1X HALT protease
inhibitor, and 1X HALT phosphatase inhibitor). A total of 45mg of protein was used for each
experiment. The pellets were re-suspended in the lysis buffer and incubated on ice for 10 minutes
with intermittent vortexing. The cells were sonicated two times for 30 seconds each at 15-W output
with 1 minute cooling on ice between bursts. Lysates were centrifuged at 20,000 rpm for 15
minutes at 15°C. The supernatant was collected in a fresh 15mL conical tube and the concentration
was determined via Bradford Assay. The cleared supernatant was diluted with lysis buffer to a
concentration of 4mg/mL to avoid protein aggregation problems. Supernatants were then reduced
with 1/10 volume of 45mM DTT for 20 minutes at 60°C and cooled on ice for 10 minutes. Reduced
lysates were alkylated with the same volume of 110mM iodacetamide as the DTT and incubated in
the dark at room temperature for 15 minutes. The samples were diluted 1:4 with 20mM HEPES, pH
8.0 and methanol-chloroform precipitation of proteins was performed. Briefly, 4X the volume of
100% methanol was added to the sample, mixed well, and centrifuged at 9,000 rpm for 10 seconds
at room temperature. Then 1X the volume of chloroform was added, mixed well, and centrifuged at
3,500 rpm for 1 minute followed by 3X the volume of HPLC grade water, mixed well, and
centrifuged at 4,000 rpm for 14 minutes. The upper layer was then removed and discarded. Next,
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3X the volume of methanol was added, mixed, and centrifuged at 9,000 rpm for 2 minutes. The
supernatant was removed and discarded, while the pellet was allowed to air dry. The pellet was resuspended in 4M urea, 50mM Tris-HCl, pH 8.8 buffer at a concentration of 3mg/mL. The sample
was then diluted to 1M urea with 50mM Tris-HCl, pH 8.8 and digested overnight at room
temperature with LysC (Wako 129-02451 10AU) in a 1/100 enzyme/protein ratio. Digested peptide
lysates were desalted over Sep-Pak® C18 Columns, volume 0.7mL (Waters WAT05910). Peptides
were eluted with 40% acetonitrile, 1% FA, lyophilized for two days and then stored at -80°C.
Immunoprecipitation- Lyopholized peptides were re-suspended in 1.4mL of 1X IAP buffer
and centrifuged at 1,800 rpm for 5 minutes. The resulting supernatant was pipetted directly into a
slurry containing PTMScan® Immunoaffinity beads and mixed overnight at 4°C. The beads were
then pelleted by centrifugation for 30 seconds at 1,500 rpm and washed twice with 1mL of 1X IAP
buffer as well as three times with 1mL HPLC grade water. Peptides were eluted from the beads
with 55μL of 100mM FA for 10 minutes at room temperature, followed by a second elution of
45μL of the same solution. The sequential elutions were combined and desalted as previously
described [100]. Finally, samples were re-suspended in 5% ACN/5% FA prior to MS analysis.
Mass Spectrometry Analysis- All samples were analyzed via LC-MS on an LTQ-VelosOrbitrap mass spectrometer configured as described previously [93] and operated in data-dependent
mode with low-resolution ion trap mass spectra acquired for the top ten precursors identified in
each MS survey scan. Data were then searched using Sequest [94] and resulting peptide and protein
identifications were filtered to a final protein-level FDR of 1% using the target-decoy approach as
described previously [95, 98]. Site localization was evaluated via AScore [101] and finally
phosphopeptides were grouped according to the phosphorylation sites they contained.
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2.2.6 Subdomain Location of Phosphorylation Sites in Protein Kinases
Putative kinases were selected from the table of all phosphorylated proteins based on the
appearance of the string “kinase” in the sequence description. From these, we identified and aligned
30 eukaryotic protein kinase domains using the program MAPGAPS [102] and sequence profiles
designed for apicomplexan protein kinases [103], while additional sequences representing atypical
kinases or other kinase-associated proteins were removed from this sequence set. The alignment
regions corresponding to each sub-domain were identified according to the definition by Hanks and
Hunter [24]. An in-house Python script was used to map each observed phosphorylation site to a
subdomain or tail region, count the number of phosphorylation sites in each region, and visualize
the totals.

2.2.7 Matching Phosphorylation Sites with Kinases Using NetPhorest
Sequences of likely eukaryotic protein kinases in the NCBI Plasmodium proteome were
uploaded to the public web server for NetPhorest [104] along with lists of phosphorylated residues.
The probabilities associating each phosphorylation site with particular kinases and kinase families
were then downloaded and sorted in order of decreasing probability. The top 2.5% of putative
kinase-substrate relationships were retained and plotted as a heat map reflecting the probability that
the indicated kinase or kinase family would be expected to phosphorylate the indicated residue.
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2.3 Results and Discussion
2.3.1 Identification of 2,767 Proteins and 6,293 Phosphorylation Sites from the Intraerythrocytic
Stages of Plasmodium falciparum
To perform a comprehensive analysis of protein expression and phosphorylation across the
intraerythrocytic stages of Plasmodium falciparum, we used isobaric labeling for quantitative
analysis of Lys-C digested parasite extracts prepared from tightly synchronized ring (16 hours ± 4
hours), trophozoite (26 hours ± 4 hours), and schizont (36 hours ± 4 hours) stages. The
phosphoproteomic work flow is outlined in Fig. 5A. This quantitative proteomic analysis identified
a total of 3,365 proteins from both the proteomic and phosphoproteomic datasets. Of these proteins,
451 were human-derived, likely from contaminating RBC material, while 2,914 were of malaria
origin, representing 55% of the total predicted P. falciparum proteome (see below) (Fig. 6) [20].
After human proteins were excluded, the final data set contained 2,767 proteins obtained in the
absence of phosphopeptide enrichment (“Proteome” table in Fig. 5B) and 1,337 phosphoproteins
(out of which 1,190 were also found in the proteome analysis; see discussion below) containing a
total of 6,293 phosphorylation sites, obtained from the phosphoproteome analysis (Fig. 5B) at a
protein-level false discovery rate (FDR) of <1%. Fig. 5C displays a histogram showing how the
quantified peptide count varied across quantified proteins; at least two peptides were used for
quantification of 90% of the identified proteins, while the average number of peptides per identified
protein was 15. The observation that the vast majority of proteins were both identified and
quantified on the basis of several peptides enhances the reliability of this analysis. We identified a
total of 11,881 phosphopeptides bearing 6,293 phosphorylation sites from 1,337 proteins. In
contrast, another recent report [76] identified 7,835 phosphopeptides matching 8,463
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phosphorylation sites on 1,673 proteins. Importantly, in addition to identification, in this study we
provide quantitative analysis of the phosphorylation changes for the first time for 4,731 sites, across
the intraerythrocytic cell cycle (Fig. 5B).
Since many proteins of the Plasmodium proteome are exclusively expressed in the mosquito
stages [84, 85], and many others are restricted to liver and gametocyte stages during infection of the
human host, we propose that our present dataset likely encompasses the majority of
intraerythrocytic stage-specific proteins. Our data significantly enhances the number of
Plasmodium identified proteins observed. Several reasons underpin the greater depth of our analysis
compared to previous reports [79, 83, 91]. Firstly, by simultaneously surveying three developmental
stages, each with its own protein complement, our study encompasses a larger fraction of the
proteomic landscape. Secondly, the continuous improvements in methodology and instrument
sensitivity naturally result in an increased number of protein and phosphorylation identifications
[92].
An intriguing aspect of intraerythrocytic development of Plasmodium is the mechanism by
which parasites regulate gene expression. Based on transcriptome analysis, it was initially believed
that the majority of genes are globally controlled in a stage-dependent manner at the transcriptional
level [105, 106], but it is now generally accepted that post-transcriptional and post-translational
regulatory mechanisms have dominant roles in regulation of intraerythrocytic gene expression [79,
80]. To further understand the importance of post-transcriptional regulation in P. falciparum we
compared the dynamics across the Plasmodium proteomic landscape to those of the published
transcriptome [105]. Only the sorbitol-synchronized ring, trophozoite, and schizont transcripts were
compared to our proteomic data, as this transcriptome profile is closest to our dataset in terms of
sample preparation. Of the 2,767 proteins identified in our study, 429 were not present in the
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transcriptomics [105] data set. For a large percentage of genes (57.1%), timing of peak mRNA
expression does not coincide with maximal protein abundance (Fig. 5D). In some instances, such as
Early Transcribed Membrane Protein 10.1 (PF10_0019) and the putative protein kinase PfTKL4
(PFF1145c), the delay in protein expression is significant: transcription peaks in segmenters or in
rings, while the protein expression peaks in schizonts, suggesting that these mRNAs have a long
half-life and are not translated until the late trophozoite stage. Analysis of mRNA decay in
Plasmodium supports a long half-life of the mRNAs for these proteins [107]. Overall, our analysis
is in line with previous findings [79, 80] that post-transcriptional regulation of gene expression
plays a major role in Plasmodium.

2.3.2 Developmental Stage-Specific Distribution of Proteins
To determine the dynamics of protein expression during the intraerythrocytic cell cycle, we
first compared expression levels by calculating three ratios across the three stages (trophozoite:
ring, schizont: ring, and schizont: trophozoite). Proteins exhibiting greater than 1.5-fold difference
in abundance between any two stages, with an adjusted p value ≤0.05, were considered enriched in
that particular stage, while proteins showing less than 1.5-fold changes for all pair-wise
comparisons, or an adjusted p value >0.05, were considered globally expressed [108]. Several
abundant proteins enriched in a specific stage of intraerythrocytic development are shown in Table
1A. For example, these proteins include merozoite surface protein 1 (enriched in the ring/schizont
sample), Pfmc2-2TM Maurer’s Cleft Two Transmembrane protein (enriched in the trophozoite
sample), and ring-exported protein 1 (enriched in the trophozoite/schizont sample). Pfmc2-2TM
Maurer’s Cleft Two Transmembrane protein is a Maurer’s Cleft associated protein that has been
implicated in transporting proteins secreted from the parasite to the erythrocyte surface [109].
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Previously, its transcription has been observed during the trophozoite stage [105] and our study
shows peak protein expression also at the trophozoite stage. This pattern suggests that Pfmc2-2TM
may have a role in the translocation of secreted proteins during trophozoite maturation.
A total of 1,832 proteins were globally expressed, while 935 showed a significant change in
expression among the intraerythrocytic stages (Fig. 7A). Of these, 353 (12.8%) proteins were
enriched in the ring stage, 59 (2.1%) were enriched in the trophozoite stage, and 86 (3.1%) were
enriched in the schizont stage (Fig. 7B). The large proportion of proteins exhibiting variable
expression across stages demonstrates that the P. falciparum proteome undergoes significant
changes during the intraerythrocytic cell cycle. Next, we analyzed the expression pattern of the
33.8% of the proteome that fluctuates across the intraerythrocytic cell cycle (Fig. 7C and 7D). Of
the constitutively expressed proteins, approximately 65% are hypothetical or unclassified proteins,
which is not significantly different from their prevalence in the predicted proteome. Expectedly, a
large portion of the recognizable constitutively expressed proteins has general housekeeping and
structural functions such as energy, metabolism, protein synthesis, and transcription.

2.3.3 Stage-Specific Analysis of Functional Profiles
In an effort to understand the functional classes of identified proteins, we sorted them using
the Munich Information Centre for Protein Sequences (MIPS) catalog, with some adaptations for
classes specific to the parasite, such as proteins pertaining to malaria pathogenesis (Fig. 8) [110].
The distribution of the functional profiles is summarized in Fig. 8. Forty percent of the identified
proteins were P. falciparum hypothetical proteins. We made an effort to categorize the hypothetical
proteins into functional classes where possible, based on sequence homology to orthologs in other
organisms (Fig. 9). Proteins belonging to important functional categories such as cell cycle and
38

DNA processing (2%), cellular transport (5%), interaction with the environment (3%), metabolism
(4%), protein fate (5%), protein with binding function (9%), and transcription (4%) account for
32% of the total proteins identified. Many of these classes of proteins are necessary for invasion,
proliferation, defense, and cell communication, which are critical for pathogenesis of the parasite.
Functional classification revealed some marked differences between intraerythrocytic stages. More
specifically, the “pathogenesis” functional category was not represented in the ring and trophozoite
stage proteomes, but reaches approximately 7% in the schizont stage. Furthermore, <1% of globally
expressed proteins are classified as functioning in pathogenesis. This increased enrichment of
proteins involved in the pathogenesis functional category at the schizont stage suggests the parasite
is preparing for rupture from the red blood cells and invasion of new red blood cells to continue the
pathogenic process. Another fascinating observation involves the “transcription” functional
category, which encompasses 2% of the ring stage proteome and 2.3% of the schizont stage
proteomes; however, this number significantly increases to 8.5% in the trophozoite stage (p<0.05,
Chi-Squared Test). Interestingly, “protein expression” protein levels is at its lowest during the
trophozoite stage, while proteins involved in transcription reach their highest level at the
trophozoite stage. Also, there are no proteins involved in protein synthesis with peak expression at
the trophozoite stage. This implies the parasite’s emphasis on transcription and not protein synthesis
during the trophozoite stage. This also suggests of an effort to conserve energy for subsequent
schizogony and an emphasis on post-transcriptional regulation.
Proteins were further characterized by assigning GO SLIM terms using “Generic GO” [85]
(http://go.princeton.edu/cgi-bin/GOTermMapper). A Plasmodium-specific GO analysis for
“Molecular Function” and “Cellular Component” was performed using collected PlasmoDB
identifiers. All proteins with PlasmoDB identifiers were compared to P. falciparum proteins within
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each molecular function category and cellular component category. The high percentage of proteins
identified across multiple “Molecular Function” categories and “Cellular Components”
demonstrates the depth and comprehensiveness of this analysis (Fig. 10A and Fig. 10B).

2.3.4 Developmental Stage-Specific Distribution of Phosphorylation Sites
Because reversible protein phosphorylation is an important regulator of protein activity, we
analyzed how protein phosphorylation fluctuates with the progression of the Plasmodium asexual
life cycle. Table 1B includes examples of abundant stage-specific phosphorylation events with the
most significant p values. We examined numbers of phosphorylated peptides, numbers of unique
sites, and the numbers of phosphoproteins identified in the three intraerythrocytic stages. Of the
identified phosphoproteins, 452 were differentially expressed and 758 were globally expressed (Fig.
5B). The number of phosphorylated peptides, unique phosphorylation sites, and total
phosphoproteins varied among the intraerythrocytic stages (Fig. 11A), reflecting the likely role of
protein phosphorylation in regulating developmental progression. The highest number of
phosphopeptides and phosphorylation sites was found at the schizont stage, while maximum
expression of phosphopeptides was detected at the ring stage. This finding underscores the
importance of protein phosphorylation in controlling specialized signaling networks that parasites
employ to progress through the intraerythrocytic cell cycle. A similar trend has been found in the
yeast centrosome phosphoproteome: only 54 phosphorylation sites were detected during the G1
stage, which is analogous to the ring stage in Plasmodium, but almost twice as many were detected
during mitosis, which is comparable to the Plasmodium schizont stage [111].
Seventy-five percent of phosphoproteins identified in this study contained multiple
phosphorylation sites (Fig. 11B); the majority are phosphorylated on three or more residues (Fig.
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11B). Phosphorylation on multiple residues suggests that a protein’s activity and interactions are
regulated via phosphorylation at distinct sites. Phosphorylation sites were scored using the AScore
algorithm to assess the confidence of site localization [101]. Any site with an AScore above 13 was
considered correctly localized. Ninety percent of the sites were localized to a single amino acid, and
87%-93% of sites (depending on stage) were localized (Fig. 11C).
Phosphorylation was most abundant on Ser (82%), followed by Thr (13.5%), and Tyr
(4.5%). The enriched phosphorylation of Ser residues surpasses its relative abundance among all
residues that are subject to phosphorylation (Fig. 11D), indicating a strong bias towards Ser
phosphorylation. The observed 4.5% of tyrosine phosphorylation in this study is similar to the
typical ~1%-4% tyrosine phosphorylation seen in other organisms [95, 112] which is somewhat
surprising given the absence of true tyrosine kinases in Plasmodium [21, 76, 113-115]. The
observed 4.5% tyrosine phosphorylation is higher than that reported earlier [76, 77, 116], at least in
part because our dataset includes the ring and trophozoite stages. Stage-specific tyrosine
phosphorylation levels are moderate at the ring stage (14.8%), decrease at the trophozoite stage
(2%), and increase to peak levels during the schizont stage (27.6%) (Fig. 11F). Although many
proteins were phosphorylated on multiple residues, only a small portion of Ser, Thr, and Tyr
residues within each phosphoprotein were modified (Fig. 11E).
Although tyrosine kinase activity in Plasmodium has been documented through
biochemical, pharmacological, and immunological approaches [117-120], the parasite’s kinome is
devoid of members of the tyrosine kinase group [21]. Two dual-specificity phosphatases, YVH1
and PRL, have been identified in Plasmodium [115, 120, 121], which probably account for at least
some of the observed Tyr phosphorylation. These reports also allude to the existence of reversible
Tyr phosphorylation in malaria parasites.
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We detected 226 Tyr phosphorylated proteins. Tyrosine phosphorylation of such a large
number of Plasmodium proteins in the absence of true tyrosine kinase homologues underscores the
importance of dual-specificity kinases in the parasite. Recent reports have identified tyrosine autophosphorylation in the activation loops of PfGSK2 and PfCLK3, dual-specificity CMGC kinases
[76, 77]. Tyr auto-phosphorylation activities by mammalian “dual-specificity tyrosine
phosphorylation-regulated kinases” (DYRK) have been observed [122]. Recently, the Plasmodium
NIMA-like kinase Pfnek3 has also been shown to have tyrosine auto-phosphorylation activity
[123]. Characterization of Plasmodium kinases with trans-Tyr phosphorylation ability will be an
area of considerable interest.
We examined each phosphorylation site to define those with a >1.5-fold increase or
decrease between stages. Fig. 11F illustrates the stage-specific distribution of serine, threonine,
tyrosine and overall phosphorylation. It is interesting to note that although the overall
phosphorylation of serine, threonine, and tyrosine residues varies greatly between the stages, the
distribution of phosphorylation between these residues is relatively stable as the parasite progresses
through the developmental cycle. Phosphorylation of 25% of the sites did not significantly
fluctuate, while 75% of the sites were stage-dependent (Fig. 11G and 11H). Our data indicate that
each stage of the P. falciparum intraerythrocytic cell cycle displays a distinct phosphoproteome
(Fig. 11G and 11H). Peak protein phosphorylation was observed in the schizont stage, suggesting
that reversible protein phosphorylation is presumably a regulatory feature of nuclear division and
merozoite ontogeny. The importance of phosphorylation in merozoite invasion has been
demonstrated previously [21, 124]. More recently, the phosphorylation of glideosome motor
components and other proteins with known involvement in parasite egress and invasion have been
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documented, supporting the involvement of phosphorylation in egress and invasion regulation
[116].

2.3.5 Distribution of Phosphorylation Site Classes and Phosphorylation Motifs Across P.
falciparum Stages and Phosphoproteins
The phosphorylation sites were analyzed to determine the kinase classes responsible for the
modification. We used a decision tree approach to classify each site as acidic, basic, prolinedirected, tyrosine, or other based on the identities of surrounding amino acids [92, 95]. Acidic sites
were the most common (36%) followed by basic (29%), while tyrosine and proline-directed sites
were the least common (4% each) (Fig. 12A). Approximately 60% of phosphoproteins contained
phosphorylation sites from multiple kinase classes, whereas 2% of phosphoproteins were predicted
to be targets for all kinase classes (Fig. 12B). Variations were detected in the frequencies of these
classes across the developmental stages, suggesting that distinct kinases operate preferentially at
various stages. Overall, site classes were represented to a much lesser extent during the early stages
(ring and trophozoite), where phosphorylation levels were the lowest, and increased drastically as
the parasite progressed into the schizont stage (Fig. 12C). Proline-directed sites that are utilized by
CDKs and MAP kinases had the most significant increase at the schizont stage (Fig. 12C).
The P. falciparum genome is extremely A:T rich, which results in an unusual amino acid
bias in the parasite’s proteome. Our analysis suggests that P. falciparum codon bias has led to
unique phosphorylation motifs that direct its kinase specificity. The phosphoproteomic data enabled
us to identify parasite-specific phosphorylation motifs using the MotifX algorithm [125]. To this
end we inputted all the identified phosphorylation sites along with six amino acids N- and Cterminal of the phosphorylated residue, generating a list of motifs that were enriched in the
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phosphorylation sequences compared to randomly selected Ser, Thr, and Tyr residues. A total of 43
distinct phosphorylation motifs were identified. Of these, 33 motifs related to phosphorylated Ser
residues and 10 motifs to phosphorylated Thr residues. Interestingly, some of the identified motifs
are unusual. For example, there are 14 motifs with prominent Asn residues, in line with an earlier
report for the schizont phosphoproteome [76]. The overall trends of phosphorylation for the
identified Ser, Thr, Arg, Asn, Gly, and Pro-residues containing motifs resemble the general trend of
phosphorylation. One notable difference is the substantial increase in phosphorylation at the
trophozoite and schizont stages for proline-containing phosphorylation motifs (Fig. 12D).
Our data provides an opportunity for the discovery of substrate motifs that may point to
specific kinases, which will help to delineate the parasite signaling networks. We predict possible
kinase-substrate relationships by comparing phosphorylated peptide sequences to protein Ser/Thr
kinase consensus phosphorylation sequences. Fig. 12E lists five putative substrates with consensus
phosphorylation sequences for known human Ser/Thr kinases. In addition to proline-containing
CDK-like motifs, we found motifs similar to those for mammalian GSK3, TGF-βR1, and numerous
other candidates. We also identified some previously undescribed motifs that are likely to be
specific for as of yet unknown kinases.

2.3.6 Phosphorylation Profiles of Putative MAPK/CDK Substrates and Tyrosine Phosphorylated
Proteins
The intraerythrocytic development of the malaria parasite diverges from the eukaryotic cell
cycle paradigm that has emerged largely from studies in yeast cells. The six identified CDK-related
protein kinases [21, 112] are likely key regulators of cell cycle progression. To validate this
prediction and gain insight into physiological functions of Plasmodium CDK-related kinases, it is
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necessary to identify their cellular substrates. CDKs are proline-directed serine/threonine kinases
having a strong requirement for basic amino acids, Arg and Lys in particular, at the +3 site [126].
Filtering 206 proline-directed Ser/Thr phosphorylated proteins for those with the strong CDK
consensus pS/T-P-X-K/R motif identified 45 proteins that are putative Plasmodium CDK
substrates. Among the proteins that may be phosphorylated by Plasmodium CDKs are homologs of
origin recognition complex subunit 2 (Orc2) (MAL7P1.21), Orc4 (PF13_0189), and Orc1/CDC6
(PFE0155w), components of the pre-replication complex that are known CDK substrates in other
eukaryotes. Additional pre-replicative complex proteins that are phosphorylated at the weak CDK
consensus motif (pS/T-P) are MCM4 and MCM5. Mammalian ORC and MCM subunits are
phosphorylated by CDKs to prevent helicase loading beyond G1 phase of the cell cycle, thus
preventing re-replication [127, 128]. Other proteins of significance in potentially regulating the
parasite’s DNA replication, transcription, or mitosis that are phosphorylated at the strong CDK
motif are homologs of cell division cycle protein 48 (PFF0940c) and regulator of chromosome
condensation (MAL7P1.38).
Developmental stage-specific protein phosphorylation profile analysis using phosphoMAPK/CDK substrates antibody demonstrated minimal phosphorylation at the ring stage and
maximal phosphorylation at the schizont stage (Fig. 13A). This correlates well with our protein
phosphorylation analysis of the 45 putative MAPK/CDK substrates, concurring that CDK activity is
predominant in late stages of the asexual cycle (Fig. 13B). Using an antibody-based pull-down of
phospho-motif peptides (PTMScan® Direct Cell Signaling Technology) in duplicate experiments,
we identified a total of 48 unique phosphorylation events. Significantly, the PTMScan®
Immunoprecipitation identified two phosphorylation events, homologs of cell division cycle protein
48 (PFF0940c) (S512) and regulator of chromosome condensation (MAL7P1.38) (S602) that were
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predicted MAPK/CDK substrates from the global phosphoproteomic analysis. Furthermore, 7 of the
identified phosphopeptides identified in the PTMScan® Immunoprecipitation were also identified in
the global phosphoproteomic analysis.
We used a phospho-tyrosine specific monoclonal antibody (P-Tyr-100) for western blot
analysis of stage-specific extracts (Fig. 13C) to demonstrate that tyrosine phosphorylation events
also fluctuate with cell cycle progression (Fig. 13D). It is evident from these data that
phosphorylation of tyrosine residues is quite common in Plasmodium. Therefore, we examined the
sensitivity of the parasite to the common tyrosine kinase inhibitors Genistein, Herbimycin, PP1, and
PP2. The observed IC50 values were as follows: Genistein 83μM, Herbimycin 0.3μM, PP1 2.4μM,
and PP2 0.9μM (unpublished data), which reveals that P. falciparum is quite sensitive to tyrosine
kinase inhibitors. Herbimycin and PP2, inhibitors of Src-family kinases, exhibited submicromolar
potency. Recent data implicating host erythrocyte signaling pathways in parasite survival [129]
suggest that some of these effects may be mediated by host tyrosine kinases. Our data suggest that
tyrosine kinases may prove to be promising targets for future malaria therapeutics developments.
A characteristic of Plasmodium intraerythrocytic cell cycle is the formation of
multinucleated schizonts through multiple nuclear divisions without cytokinesis [17]. In addition to
CDKs, Aurora kinases play important roles in the regulation of mitosis in eukaryotes; thus we
identified putative substrates of Plasmodium Aurora kinase A homologues using an Aurora kinase
A phosphorylation motif, (K/R)-(K/R)-X-(pS/pT)-L. Our data filtering identified proteins with a
MORN-repeat, Kid domain, and MIF4G domain among 28 putative Plasmodium Aurora kinase A
substrates. A MORN repeat-containing protein has been shown in another apicomplexan parasite,
Toxoplasma gondii, to be a component of cell division machinery [130].
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2.3.7 Sub-domain Distribution of Phosphorylation Sites within Protein Kinases
Because a common regulatory mechanism of eukaryotic phosphosignaling pathways is the
auto-phosphorylation of key regions of the kinase domain itself, we investigated the subdomain
distribution of phosphorylation in Plasmodium kinases. Thirty of the phosphorylated proteins from
our phosphoproteomic data set were identified as eukaryotic protein kinases (ePKs). In these
proteins we identified the location of each of the 126 observed phosphorylation sites relative to the
kinase domain, whether in the kinase domain, the N-terminal tail, or the C-terminal tail. Those in
the kinase domain were further assigned to a sub-domain location (Fig. 14A). The majority of
phosphorylation sites, 71 in total, appear in the N-terminal extension of the kinase domain, while 25
appear in the C-terminal tail and 30 appear in the kinase domain itself. This apparent enrichment in
the N-terminal extension region is mostly explained by the presence of extended N-segments in
many of the P. falciparum protein kinases.
When examining the stage-specific expression profile of the 30 identified ePKs, we
observed peak expression at the ring stage (Fig. 14B). This is in contrast to the stage-specific profile
of phosphorylation of these kinases, which exhibits peak phosphorylation at the schizont stage (Fig.
14B). Furthermore, the percentage of ePKs with global expression is large (30%) in comparison to
the 11% of global phosphorylation events. Fig. 14C depicts the stage-specific distribution of the
number of phosphorylation sites at a given time during the intraerythrocytic cell cycle for each of
the kinase sub-domains, as well as the N-terminal and C-terminal tails, where overall
phosphorylation levels are the highest at the trophozoite and schizont stages.
The protein kinase sub-domains VII and VIII contain the activation loop, a structural region
whose phosphorylation is a key step in the activation of many kinases [131]. We observed
activation loop phosphorylation in three kinases: PfCDPK1 (PFB0815w), PfCRK3 (PFD0740w),
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and an orphan kinase (PF11_0227). Of these, the single phosphorylation sites on PfCDPK1 and
PfCRK3 are consistent with a typical mechanism of kinase activation by phosphorylation of the
activation loop, while the orphan kinase PF11_0227 contains a greatly extended activation loop of
135 amino acids, of which three were phosphorylation sites, suggesting the possibility of a novel
functional elaboration.
Phosphorylation in sequence regions between the defined sub-domains was observed in two
kinases, FIKK4.1 (PFD1165w) [132] and PfPK1 (PF08_0044), which is related to glycogen
synthase kinases [103, 133] (Fig. 14A). The N-termial region of subdomain VIb, which includes the
catalytic loop and beta-7 strand, was phosphorylated in two other kinases, PfSRPK1 (PFC0105w) at
6 sites and the orphan kinase PF14_0392 at 3 sites. In PfSRPK1 this is the site of a large insert
known as the spacer domain, which influences localization of the protein in yeast and human
SRPKs [134]. Given that the spacer region itself if not required for PfSRPK1 activity [135], the
extensive phosphorylation of the spacer region of PfSRPK1 may instead be a mechanism
controlling localization or binding of PfSRPK1.
While tyrosine phosphorylation is rare overall in the P. falciparum phosphoproteome [7678], those occurrences are noteworthy as they may point to novel signaling pathways or
mechanisms in the parasite. We observed only one phosphorylated tyrosine site within the kinase
domain, in subdomain IV of PfCRK4 (PFC0755c). Structurally, this is the beta-4 sheet in the ATPbinding N-lobe of the kinase domain; PfCRK4 was also phosphorylated on serine or threonine
residues at 6 other sites in subdomain IV. Four more instances of tyrosine phosphorylation were
observed in the N-terminal tails of PfCRK4, PfCRK1 (PFD0865c), PfPKG (PF14_0346), and the
orphan kinase PF14_0392. In previous studies tyrosine phosphorylation has been observed in the
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activation loop of dual-specificity kinases such as PfGSK3 and PfCLK3 [77]. However, we did not
find any instances of tyrosine activation loop phosphorylation in this study.

2.3.8 Preliminary Identification of Kinases Responsible for Kinase Domain Phosphorylation
The activity of each kinase in signaling cascades is determined in part by specific reversible
phosphorylation events. Since these phosphorylation events govern the activities of these kinases,
identifying the kinases responsible can reveal the phosphorylation networks that regulate
Plasmodium biology. We used a computational approach to predict those kinases that are likely
responsible for observed kinase phosphorylation events. Though such predictions on their own do
not prove particular kinase-substrate relationships, they nevertheless can provide working
hypotheses that can be tested experimentally. We used the NetPhorest algorithm [104] to identify
candidate kinases that may be responsible for the 126 phosphorylation events we observed upon 30
Plasmodium kinases. The 2.5% most likely kinase-substrate pairings are depicted in Fig. 15 for all
phosphorylation sites observed on Plasmodium kinases in conjunction with structural and
quantitative data.
Although 22 kinases and kinase families are associated with the 126 kinase phosphorylation
sites, the most confident predictions implicated kinases of the CK2 family (similar to Casein Kinase
2). Sites on nearly a dozen kinases were located in highly acidic regions that were judged to be
favorable for CK2 activity; essentially all of these sites reached maximum abundance during the
schizont stage, which is consistent with shared regulation. In contrast, two sites on separate kinases
bear a signature SQ motif that are predicted to be substrates for ATM/ATR kinases; however, while
one of these sites reaches maximum expression during the schizont stage, the other peaks during the
ring stage and is nearly completely absent during the trophozoite stage. Finally, we observed a
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single phosphorylation site on NEK1, which was scored as a candidate substrate for DMPK, PAKB,
or a NEK-family kinase: thus, this site could potentially be a case of auto-phosphorylation.

2.3.9 Peak Protein Expression and Phosphorylation are Unlinked
Differential levels of phosphopeptide detection can arise from changes in protein level, or
from genuine changes in the phosphorylation occupancy of the target site. In order to differentiate
between these two possibilities, we compared the proteomic data of the intraerythrocytic stages to
our phosphoproteomic analysis. Overall, we identified 2,914 proteins, 40% of which were identified
both with and without enrichment of phosphopeptides (Fig. 16A). A similar overlap was observed
across developmental stages (Fig. 16B). The proteins that are identified solely on the basis of
phosphorylation data are those of low abundance. Very low abundance proteins are often difficult
to detect using the shotgun approach that we used, but when they are phosphorylated they can often
be identified following phosphopeptide enrichment.
Phosphorylated and non-phosphorylated protein profiles varied throughout the asexual cell
cycle (Fig. 16C). Seventy-five percent of proteins with stage-specific phosphorylation sites were
expressed across multiple intraerythrocytic stages in the non-phosphorylated form (Fig. 16D). In
general, protein expression and phosphorylation display obvious differences throughout the P.
falciparum intraerythrocytic cell stages. Malaria parasite protein expression can be classified as a
global event (66.2%) more frequently than is observed for protein phosphorylation (25%). Among
those proteins that are variably expressed across developmental stages, a significant number
attained peak expression during ring stage in contrast to the phosphorylation, which peaks at the
schizont stage, demonstrating that peak phosphorylation events are generally not due to stagespecific protein expression.
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Proteins and phosphorylation sites that showed statistically significant differences in protein
abundance, phosphorylation levels, or both across the three growth stages were classified via Kmedoids clustering into groups with similar patterns of both protein expression and
phosphorylation. The silhouette method was then used to determine the optimal number of clusters
for the data, which showed 7 clusters in our case. Fig. 17A summarizes numbers of proteins and
phosphorylation sites that were assigned to each of the 7 clusters, accompanied by the trends
observed for proteins and sites in each group. Also, heat maps were generated for each cluster to
illustrate changes in protein expression and phosphorylation. The results suggest that protein
abundance and phosphorylation levels change independently of one another. There are relatively
few cases where both change in tandem, while there are many cases where phosphorylation
increases while protein abundance stays the same or decreases. For example, in cluster PEP3, there
are 1,526 phosphorylation sites with associated protein measurements. Members of this cluster
generally showed increasing levels of phosphorylation while protein levels decreased (Fig. 17A).
In an effort to further characterize the proteins in each of the 7 clusters and demonstrate that
membership in a cluster is nonrandom; we examined the functional classes of all of the proteins in
each cluster using the MIPS catalogue. Interestingly, some of the 7 clusters show a significant
enrichment in functional classes. When applying a Chi-Squared test and determining a two-tailed p
value for each cluster, the distribution of functional classes proved to be highly nonrandom. This
signifies that proteins following similar expression and phosphorylation trends also possess similar
functional roles. The percentage of proteins in each functional category for each cluster can be seen
in Fig. 17B. A remarkable trend can be seen for Cluster PE2 functional analysis. Cluster PE2
proteins show a slight increase in protein expression at the schizont stage, while the parasite
prepares for egress from the erythrocyte and invasion into a new host cell. Supporting this is the
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fact that 100% of proteins in the Host Invasion, Entry into Host-Cell, and Antigenic Variation
functional categories are members of cluster PE2. Another interesting trend can be seen for cluster
PEP3, which comprises a significant number of cell cycle regulatory proteins. Cluster PEP3 shows
a dramatic increase in protein phosphorylation at the schizont stage. This is the period in the
Plasmodium developmental cycle where multiple rounds of DNA replication are ongoing. The fact
that approximately 29% of proteins in the Cell Cycle and DNA Processing functional category are
members of Cluster PEP3 demonstrates the involvement of phosphorylation in the control of P.
falciparum cell cycle progression.

2.4 Conclusions
This is the only quantitative study that compares dynamics of phosphorylation events as the
parasite progresses through its asexual developmental stages in the host erythrocyte. A major
challenge in the post-genome sequencing era is to understand the cellular roles of the vast number
of proteins whose function is not deducible from sequence analysis. Achieving a comprehensive
functional understanding of the Plasmodium falciparum proteome is particularly challenging, given
that 60% of putative proteins have no known orthologs in other systems. Many Plasmodium
proteins, including kinases, are atypical and possess hybrid features [136]; thus, this work brings a
significant contribution to the ongoing global and multi-pronged efforts at implementing functional
genomics studies of Plasmodium falciparum, the end goal of which is to facilitate the discovery of
novel targets for intervention. Our phosphoproteomic analysis also represents a step toward
elucidation of the kinase-substrate pairs that will eventually form the basis of a comprehensive
Plasmodium signaling network. In view of the phylogenetic divergence of malaria parasites relative
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to model eukaryotes such as yeast and mammalian cells, this is likely to shed light from a different
angle on a domain that is of central importance in biology.
Data from this study are available at http://plasmodb.org/plasmo/
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Figure 4: Identification of the Phosphoproteome and Proteome from the Intraerythrocytic
Stages of Plasmodium falciparum
(A) Overview of the procedure for phosphopeptide preparation and enrichment from stage-specific
P. falciparum lysates. Duplicate samples from each stage were processed to generate the lists of
proteins and phosphorylation sites. Protein samples were digested with LysC, followed by labeling
with TMT and fractionation on a SCX column. Enrichment of phosphopeptides was conducted
using IMAC. The resulting phosphopeptide samples were analyzed on an LTQ-Velos Orbitrap mass
spectrometer. Spectra were identified using SEQUEST, and the resulting data were filtered to a
protein-level false discovery rate of 1%. AScore was used to assess phosphorylation site
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localization. Phosphorylation sites with AScores above 13 were considered to be localized. (B)
Tables representing the total numbers of stage-specific distributions of identified peptides and
phosphopeptides, phosphorylation sites (before AScore filtering), and proteins and phosphoproteins
in the six stage-specific samples indicated to the left. (C) Histogram depicting the numbers of
peptides used for identification and quantification of the proteins reported in this study. (D)
Correlation of the transcriptome (as stated on PlasmoDB) and the proteome of identified malaria
proteins.
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Figure 5: Distribution of Identified Human vs. Malaria Proteins and Phosphorylation Sites
(A) Comparison of the number of human and malaria proteins identified in the proteomic analysis.
(B) Percentage of human and malaria phosphorylation sites identified in the phosphoproteomic
study.
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Table 1: Quantification of Stage-Specific (A) Proteins and (B) Phosphorylation Sites
Table 1A: Quantification of Stage-Specific Proteins
Stage
Peak
Expression

Accession
Number

Annotation

Adj. pValue

Peptide
Count

Ring
Average

Trophozoite
Average

Schizont
Average

1.81472E-69

426

0.19822

0.12845

0.17333

1.98323E-26
1.94174E-23

173
31

0.20033
0.20973

0.12982
0.12672

0.16985
0.16355

4.9966E-181

123

0.26665

0.14896

0.08438

2.9399E-151

148

0.25202

0.14008

0.10789

2.7421E-138

108

0.25039

0.13255

0.11706

Heat Shock Protein 86
Enolase
L-Lactate
Dehydrogenase

5.2475E-178
2.1139E-152

403
249

0.21866
0.22732

0.16784
0.16188

0.11350
0.11079

9.3727E-118

171

0.23005

0.15436

0.11559

Heat Shock Protein 90
Mature ParasiteInfected Erythrocyte
Surface Antigen
(MESA) or PfEMP2
Pfmc-2TM Maurer’s
Cleft Two
Transmembrane
Protein

5.62519E-73

62

0.14727

0.26304

0.08969

2.44953E-66

132

0.13203

0.25505

0.11292

2.86193E-51

84

0.13169

0.22994

0.13838

Ring-Exported Protein
1
Conserved
Plasmodium Protein
RecName: Full= RingInfected Erythrocyte
Surface Antigen

1.08717E-44

89

0.07421

0.21638

0.20940

2.85479E-44

190

0.12001

0.18267

0.19732

4.38793E-30

73

0.08755

0.18778

0.22466

2.59184E-42

126

0.13449

0.15767

0.20784

5.28286E-26

49

0.11808

0.10549

0.27644

8.48E-26

54

0.15048

0.08967

0.25985

Schizont/
Ring
A5A7B0
Q4AE85
Q8I2J4

Merozoite Surface
Protein 1
RhopH1/ Clag3.1
Profilin

Ring
Q6LFH8
Q8IDQ9
Q8IJA9

Ornithine
Aminotransferase
Phosphoethanolamine
N-Methyltransferase
Adenosine Deaminase

Ring/
Trophozoite
Q8IC05
Q8IJN7
Q71T02

Trophozoite
Q8III6
Q8I492

Q8IJ11

Trophozoite/
Schizont
Q8I2G1
Q8ILA1
P13830

Schizont
Q8I5M3
Q8IJQ4
Q8IDR3

Conserved
Plasmodium Protein
Conserved
Plasmodium Protein
Myosin A
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Table 1B: Quantification of Stage-Specific Phosphorylation Sites
Stage
Peak
Phosphorylation

Accession
Number

Annotation

Adj.
pValue

Peptide
Count

Class

Ring
Average

Trophozoite
Average

Schizont
Average

Site

5.67584E-05

8

A

0.23169

0.14715

0.16912

S406

0.000263595

3

O

0.24748

0.11807

0.18188

S1296

0.001019579

9

A

0.21974

0.13337

0.19774

S1288

2

O

0.22058

0.13932

0.14850

S25

8.91046E-11

3

A

0.36738

0.09242

0.07079

S2603

1.436E-09

8

B

0.35644

0.08576

0.06399

S99

4.05683E-09

19

A

0.26736

0.14217

0.11477

S513

2.50453E-09
1.201E-08

14
4

B
O

0.25089
0.30932

0.17959
0.25867

0.13337
0.05553

T192
T23

5.25165E-07

4

O

0.30742

0.26047

0.06233

S22

1.68106E-06

9

B

0.24925

0.17173

0.14156

S275

8.66673E-11

7

O

0.12973

0.41704

0.13912

T136

3.16966E-07

6

A

0.16576

0.32821

0.11905

S16

1.52967E-05

7

A

0.12416

0.21326

0.17549

S177

Schizont/
Ring
O97239

Q8ILC8

C6KT13

Conserved
Plasmodium
Protein
DNA
Topoisomerase
II
Conserved
Plasmodium
Protein

0.006320528

Ring
Q8I296

C5HEV4

Q7K6A5

Ubiquitin
CarboxylTerminal
Hydrolase
RhoptryAssociated
Protein 1
Multi-Drug
Resistance
Protein

Ring/
Trophozoite
Q8IDQ2
P39898

O97238

Trophozoite
Q8IDG8

Q8IDM6

Q8I492

Trophozoite/
Schizont

Q8IJW6

Q8I3A3
Q8IB78

Schizont
Q8ILA9

Q8IC17

Q8IHR4

Kelch Protein
RecName:
Full=
Plasmepsin 1
Conserved
Plasmodium
Protein
MembraneAssociated
Histidine Rich
Protein 2
Nucleoside
Transporter 1
Mature
ParasiteInfected
Erythrocyte
Surface
Antigen
(MESA) or
PfEMP2

Transcription
Factor with
AP2 Domain
Ubiquitin
Specific
Protease
Nucleoside
Transporter
Conserved
Plasmodium
Protein
Origin
Recognition
Complex
Subunit 2
Dynamin-Like
Protein

25

A

0.06787

0.23552

0.27157

S913

1.19618E-24

16

A

0.06456

0.24616

0.28399

S907

2.27714E-23

14

P

0.05212

0.24595

0.30015

S918

9.15377E-22

16

A

0.08560

0.21405

0.29959

S1457

1.64292E-20

10

O

0.02631

0.35909

0.28085

T336

1.86363E-22

18

P

0.07735

0.16488

0.29758

S121

7.10986E-19

11

T

0.13324

0.22689

0.37323

S347

7.40701E-19

16

O

0.12588

0.14555

0.24440

S782

2.3356E-35
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Table 1: Quantification of Stage-Specific (A) Proteins and (B) Phosphorylation Sites
(A) Stage-specific abundant proteins exhibiting a >1.5-fold difference in expression among
intraerythrocytic stages. The representative proteins for each stage displayed the most significant p
values. The columns corresponding to the ring average, trophozoite average, and schizont averages
are the normalized intensities for peptides associated with each particular stage. (B) Stage-specific
abundant phosphorylation sites exhibiting a >1.5 fold difference in phosphorylation levels among
intraerythrocytic stages. The proteins for each stage displayed the most significant p values. Site
classes were assigned using a decision tree algorithm: A: acidic; B: basic; P: proline-directed; T:
tyrosine; O: other. The columns listing the ring average, trophozoite average, and schizont averages
are the normalized intensities for phosphorylated peptides associated with each stage.
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Figure 6: Comparative Analysis of Stage-Specific Protein Expression
(A) Venn diagram depicting the distribution of identified malaria proteins over the intraerythrocytic
stages. (B) Percentage of globally expressed proteins and proteins quantified at each of the
intraerythrocytic stages. (C) Expression level changes as determined by a >1.5-fold difference. (D)
Number of proteins up- and down-regulated in each stage in comparison with ring stage expression
levels.
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Figure 7: Stage-Specific Analysis of Functional Profiles
Functional profiles of expressed proteins using GO annotations downloaded from PlasmoDB
(www.plasmodb.org) or UniProt (www.uniprot.org) as defined by the MIPS catalogue. To avoid
redundancy, we assigned only one class per protein.
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Figure 8: Functional Profile of Hypothetical Proteins
The functional profile of hypothetical proteins was generated using GO annotations downloaded
from PlasmoDB (www.plasmodb.org) or UniProt (www.uniprot.org) as defined by the MIPS
catalogue. To avoid redundancy, only one functional class was assigned per protein.
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Figure 9: Gene Ontology Term Analysis of Intraerythrocytic Stage

(A) Enrichment for GO “Molecular Function” terms of proteins detected in P. falciparum intraerythrocytic stages. The figure
shows the percentage of GO terms identified in our proteomic data compared to terms of all predicted P. falciparum proteins. (B)
Enrichment for GO “Cellular Component” terms of proteins detected in the intraerythrocytic stages. The number of each “Cellular
Component” identified in our proteomic data is compared to all predicted P. falciparum proteins. The percentage identified in our
data for each component is shown.
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Figure 10: Global Analysis of Stage-Specific Phosphorylation Patterns
(A) Relative distributions of stage-specific phosphopeptides, phosphorylated sites, and
phosphoproteins. Raw values are provided in Figure 5B. (B) Histogram depicting the numbers of
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phosphorylation sites identified for each phosphorylated protein. (C) Distribution of the number of
localized and non-localized phosphorylation sites throughout the intraerythrocytic stages. (D)
Relative abundance of serine, threonine, and tyrosine residues within all phosphoproteins compared
with their frequency of phosphorylation. (E) Extent of phosphorylation of serine, threonine, and
tyrosine residues within all phosphoproteins. (G) Venn diagram depicting the distribution of
identified malaria phosphorylation sites over the intraerythrocytic stages. (H) Phosphorylation level
changes as determined by a >1.5-fold difference in comparison with observed ring stage levels.
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Figure 11: Stage-Specific Distribution of Phosphorylation Site Classes and Motifs
Phosphorylation sites were categorized as acidic, basic, proline-directed, tyrosine, or other as
previously described [95]. (A) Overall percentage of each site class and percentage of each
throughout the intraerythrocytic cell cycle of P. falciparum. (B) Proportion of phosphoproteins
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containing phosphorylation sites from only one site class, from two, three, or four different site
classes, or from all five different site classes. (C) Proportion of residues phosphorylated in each site
class through the intraerythrocytic stages. (D) Comparison of phosphorylation across the P.
falciparum intraerythrocytic stages for motifs containing serine, threonine, arginine, asparagine,
glycine, and proline residues. (E) Table identifying potential Ser/Thr kinases responsible for
observed phosphorylation on representative putative substrates.
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Figure 12: Phosphorylation Profiles of Putative MAPK/CDK Substrates and Tyrosine
Phosphorylated Proteins
(A) Immunoblot analysis using a MAPK/CDK phospho-specific antibody on 8 hour time point
lysates. (B) Analysis of 45 putative MAPK/CDK substrates revealing the number of proteins with
peak expression in each stage and the number of phosphorylation events peaking at each stage. (C)
Immunoblot analysis using a phospho-tyrosine antibody on 8 hour time point lysates. (D) Stagespecific distribution of proteins containing tyrosine phosphorylation events.

68

Figure 13: Subdomain Location of Phosphorylation Sites in Protein Kinases
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(A) Subdomain location of 126 phosphorylation sites observed on 30 eukaryotic protein kinases.
Bar height indicates the number of observed phosphorylation sites relative to the kinase domain,
whether in the domain, the N-terminal tail, or the C-terminal tail. Those in the kinase domain were
further assigned to a subdomain location. (B) Stage-specific comparison of eukaryotic protein
kinase expression levels and phosphorylation levels. (C) Histogram depicting the stage-specific
distribution of the number of phosphorylation sites at a given time during the intraerythrocytic cell
cycle for each of the kinase subdomains as well as the N-terminal tail and C-terminal tail.
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Figure 14: Associating Kinase Subdomain Phosphorylation Events with Probable Kinases
Those localized phosphorylation events that mapped to known kinase subdomains were analyzed
using NetPhorest to identify the kinase or kinase groups most likely to phosphorylate each site
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based on neighboring sequences [104]. A total of 22 kinases and kinase groups accounted for the
most confident 2.5% of all predicted kinase-site relationships and are mapped below. The red heat
map displays the predicted confidence that each kinase or kinase family would phosphorylate the
sequence in question; the yellow heat map displays relative levels of each phosphorylation site
throughout three stages of the Plasmodium life cycle.
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Figure 15: Comparison of Protein and Phosphoprotein Expression Across P. falciparum
Intraerythrocytic Stages
(A) Comparison of proteins identified with and without phosphopeptide enrichment. (B) Numbers
of proteins and phosphoproteins with peak expression at each of the intraerythrocytic stages. (C)
Stage-specific comparison of protein expression and phosphorylation levels. (D) Bar chart
reflecting proportions of proteins with global, moderate, and stage-specific expression in an
unmodified form, modified form, and those containing stage-specific phosphorylation sites.
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Figure 16: K-Medoids Cluster Analysis of Differential Proteins
(A) Proteins and phosphorylation sites that showed statistically significant differences across the three growth stages in protein
abundance, phosphorylation levels, or both were classified via K-Medoids clustering. The numbers of proteins and
phosphorylation sites that were assigned to each cluster as well as the trends observed for protein expression and phosphorylation
are depicted. (B) Functional profiles of proteins in each cluster using GO annotations downloaded from PlasmoDB
(www.plasmodb.org) or UniProt (www.uniprot.org) as defined by the MIPS catalogue.
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CHAPTER 3: PHOSPHOPROTEOMIC ANALYSIS OF PLASMODIUM
FALCIPARUM REVEALS SUBSTRATES OF THE ATYPICAL KINASE
PFPK7
3.1 Summary
Options for malaria therapy is increasingly becoming limited because of widespread drug
resistance. Therefore, there is a need to identify new pharmacophores targeted against novel targets.
Atypical Plasmodium protein kinases are considered to be ideal targets due to the distinct structural
and functional characteristics in comparison to their host. Plasmodium falciparum protein kinase 7
(PfPK7) is an “orphan” protein kinase displaying regions of homology to more than one protein
kinase family. Furthermore, PfPK7 has been shown to be involved in regulating parasite
proliferation and development. To better understand the involvement of PfPK7 in Plasmodium
falciparum, we performed isobaric tag-based quantitative phosphoproteomics analysis of the
schizont and segmenter asexual stages in both the presence and absence of PfPK7. A total of 1,047
proteins and 3,875 phosphorylation sites were identified in the wild type and PfPK7- samples. In
order to determine which proteins PfPK7 may be phosphorylating, we examined the
phosphoproteomic data for proteins displaying decreased phosphorylation in the absence of PfPK7
during both the schizont and segmenter stages. We identified 146 proteins with a total of 239
phosphorylation sites exhibiting decreased phosphorylation in the absence of PfPK7 during both
intraerythrocytic stages. Further analysis of the decreased phosphorylation events revealed three
distinct motifs that are enriched among phosphorylated sites in Plasmodium proteins that are down
regulated. Due to this decreased phosphorylation, it is possible that these proteins may act as
substrates of PfPK7 and function in parasite proliferation and/or development. The ability of
recombinant PfPK7 to utilize these putative substrates was examined and we have demonstrated
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that PfPK7 is active towards various substrates that were predicted from the phosphoproteomics
analysis. More specifically, the atypical kinase PfPK7 was able to directly phosphorylate two
conserved Plasmodium proteins with unknown functions (PF10_0257 and PFB0490c) and 60s
ribosomal protein L7Ae/L30e putative (PFD0960c). We also determined that PfPK7 was not able to
directly phosphorylate many of the phosphorylation events that displayed decreased
phosphorylation in the absence of PfPK7, suggesting the role of PfPK7 as an upstream regulatory
kinase. Our phosphoproteomics analysis has revealed insight into the dynamics of PfPK7
phosphorylation during both the schizont and segmenter stages, while making a major step toward
defining PfPK7-substrate pairs.

3.2 Materials and Methods
3.2.1 Plasmodium falciparum Culture
The PfPK7- cell line was kindly provided by C. Doerig (Monash University, Clayton
Australia). Parasites of Plasmodium falciparum strain 3D7 and PfPK7- were grown at a 4-10%
parastemia and 4% hematocrit in RPMI 1640 culture medium supplemented with A+ erythrocytes
and 0.5% albumax as previously described [88]. Blasticidin was added to a final concentration of
2.5μg/ml in the PfPK7- cultures. Parasites were doubly synchronized as described by Pease et al.
[1]. Briefly, schizont stage parasites were magnetically synchronized using a MACS LD (Miltenyi
Biotec, Auburn , CA) column with a Midi-MACs Separator. Approximately 8 hours after MACS
synchronization, the parasites had re-infected fresh red blood cells and entered the ring stage.
Parasites were then re-synchronized by treatment with 5% sorbitol (w/v).
Parasite growth and parastemia were periodically monitored by Giemsa-stained blood
smears. Tightly synchronized schizonts (approximately 36 hours ± 4 hours post-invasion) and
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segmenters (46 hours were ± 4 hours post-invasion) were harvested following established protocols
[91]. Parasites were isolated by lysing the red blood cells in 0.1% saponin followed by thorough
washing in PBS. The subsequent parasite pellets were weighed and proteins were immediately
extracted by lysis in an 8M urea lysis buffer supplemented with protease and phosphatase inhibitors
(8M urea, 75mM Tris, pH 8.2, 1X HALT protease inhibitor, 1X HALT phosphatase inhibitor) [16].
Lysates were cleared by centrifugation for 10 minutes at 4°C at 14,000 rpm. Protein concentration
was determined for each sample by BioRad Bradford Assay. Duplicate samples were prepared for
each developmental stage and pooled.
3.2.2 PfPK7- Verification through Southern Blot Analysis and PCR Analysis
Genomic DNA was isolated from wild type 3D7 and from PfPK7- parasites. A washed
pellet of parasites obtained by saponin lysis was treated with 250mM EDTA, 2% sodium dodecyl
sulfate, and 150μg/ul RNAse at 37°C for 1 hour. Next, the pellet was treated with 150μg/ml
proteinase K at 60°C for 2 hours. The DNA was extracted with chloroform: phenol: isoamyl alcohol
(25:24:1) and chloroform: isoamyl alcohol (24:1) followed by precipitation with ethanol and 0.3M
sodium acetate. One microgram of each wild type 3D7 and PfPK7- DNA was digested with EcoRV
and NcoI. The digested DNA was then fractionated on a 0.8% agarose gel and transferred to a
Schleicher and Schuell Nytran SPC membrane. Full length PfPK7 was used as the probe. The probe
was generated using the following primers: primer 1: ATGAAGGATATTTTATCTAATTATTC
and primer 2: TTATAATTTTTTCCTCTTTTTATAAAG. The full length PfPK7 gene was labeled
with (32P)dCTP using the Prime-it II random primer labeling kit following the manufacturer’s
instructions (Stratagene). After the probe was labeled, it was purified using the QIAquick
Nucleotide Removal kit as instructed (QIAgen). Hybridization was carried out at 60°C overnight as
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described by Sambrook and Russell [137]. After thorough washing, autoradiograms of hybridized
blots were prepared using Kodak Biomax MS film exposed at -80°C with the use of an intensifying
screen.
To further verify the presence of PfPK7 in the wild type 3D7 cell line and the absence of
PfPK7 in the knock out cell line, genotype characterization through PCR analysis was performed.
Genomic DNA extracted from the wild type 3D7 cell line and PfPK7- cell line was used for
detection of a partial PfPK7 gene following the genotype characterization used when creating the
PfPK7- cell line [27]. The sequences for the primers had minor modifications, compared to the
original protocol, to remove the cut sites and amplify only the PfPK7 partial gene. The primers
were designed as follows: primer 1: ATGAAGGATATTTTATCTAATTATTCAAAC and primer
2: ACCCAAACTCCATATATCCACCTTTGC. The resulting PCR product would be 702 base
pairs in size.

3.2.3 Phosphopeptide Enrichment and Identification
Following protein extraction, samples containing 1mg of protein per stage for the wild type
3D7 P. falciparum and PfPK7- samples were reduced, alkylated, and digested with Lys-C prior to
labeling with TMT isobaric labeling reagents [87]. The resulting peptides were fractionated via
strong cation exchange chromatography (SCX). The resulting 20 fractions were subjected to
immobilized metal affinity chromatography (IMAC) to specifically pull out phosphorylated
peptides [92]. Phosphopeptides were analyzed via LC-MS/MS on an LTQ-Velos-Orbitrap mass
spectrometer as described previously [1]. Peptides were identified by matching individual MS/MS
spectra with peptide sequences using Sequest [94]. Searches employed a database containing
Plasmodium sequences from NCBI [96] as well as human protein sequences from the International
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Protein Index [97]. The peptides were filtered using a multivariate approach to remove questionable
identifications based on a target-decoy strategy [95, 98]. Peptides were assembled into proteins and
proteins were further filtered to ensure a protein-level false discovery rate of 1%. Individual
phosphorylation sites on each peptide were scored to assess how confidently the modification could
be localized to a single residue using AScore [99]. Finally, the peptides and proteins were filtered to
account for protein redundancy.
For quantification, TMT reporter ion signals were extracted from MS/MS spectra and
normalized assuming equal protein loading in each channel. Each phosphorylation site was
quantified by gathering together all matching peptides, filtering out peptides that didn’t meet our
quantification standards, and re-scaling reporter ion intensities so that they summed to 1.0.

3.2.4 Identification of PfPK7 Substrate Phosphorylation Motifs
To identify primary sequence motifs directly or indirectly associated with PfPK7 activity;
those phosphorylation sites whose abundance decreased in the absence of PfPK7 were extracted.
Sites were separated according to the residue phosphorylated (Ser, Thr, or Tyr) and enriched motifs
were identified using the algorithm Motif-X [125] to compare down-regulated sites with all Ser,
Thr, and Tyr residues in the Plasmodium proteome. Motifs were required to occur at least 10 times
among down-regulated sites and the minimum significance was set to 1e-5. While no significant
motifs were observed for Thr and Tyr sites due to their infrequent detection, three motifs were
detected for Ser phosphorylation sites.

3.2.5 Assignment as a Potential Substrate and Generation of Expression Constructs
When analyzing the wild type 3D7 and PfPK7- phosphoproteomic data sets, we compared
phosphorylation levels by calculating two ratios among the two cell lines and developmental stages
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(PfPK7- schizont: 3D7 schizont and PfPK7- segmenter: 3D7 segmenter). Phosphorylation events
exhibiting greater than 1.5-fold differences in abundance between the two cell lines were
considered enriched in that particular cell line, while phosphorylation events showing less than 1.5fold changes for both comparisons were considered phosphorylated equally in both cell lines. Of
the 3,875 phosphorylation sites identified in the phosphoproteomic analysis, 239 phosphorylation
events on 146 phosphoproteins displayed a greater than 1.5-fold decrease in phosphorylation in the
PfPK7- cell line at both the schizont and segmenter stages. In order to investigate if any of these
146 phosphoproteins are in fact substrates of PfPK7, we generated His-tagged constructs of the
potential substrates with selected open reading frames exhibiting the largest decrease in
phosphorylation in the PfPK7- cell line for both the schizont and segmenter stages and three
potential substrates containing the identified RxxS* motif whose lengths were under 2,000 base
pairs in size. The following proteins were cloned into the pET30 EK/LIC vector following the
manufacturer’s instructions (EMD Millipore): PFB0100c, PF10_0257, PF14_0068, PF10_0068,
PFD0960c, PFI1555w, PF13_0102, PFB0490c, and PF14_0190.

3.2.6 Bacterial Expression and Purification of Recombinant Proteins
The potential PfPK7 substrates were optimally expressed in BL21-CodonPlus (RIPL) cells
(Stratagene) and purified from the soluble fraction by affinity chromatography using HisLink resin
and following the manufacturer’s instructions (Promega). The plasmid encoding GST-PFPK7 were
kindly provided by C. Doerig (Monash University, Clayton Australia). The expression and
purification of GST-PfPK7 was performed following published procedures [138].
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3.2.7 In vitro Kinase Assays
Kinase reactions to measure PfPK7 auto-phosphorylation and activity toward the potential
substrates were performed using 1μg of recombinant PfPK7 and 5μg of recombinant substrate in a
total volume of 30μl as described previously [45, 139]. A standard kinase buffer containing 20mM
Tris/HCl (pH 7.5), 20mM MgCl2, 2mM MnCl2, 10μM ATP, and 5μCi (γ-32P) ATP was used.
Kinase reactions were incubated for 30 minutes at 30°C and stopped by the addition of 5X gel
loading buffer. The entire kinase reaction was loaded on a 12% SDS/polyacrylamide gel. The gels
were then stained with Coomassie blue stain, de-stained using a 30% methanol and 10% glacial
acetic acid solution, dried, and exposed for autoradiography. Signal intensity values were obtained
and normalized by using the kinase buffer control as the 0% value and PfPK7 auto-phosphorylation
as the 100% value. The ability of PfPK7 to phosphorylate potential substrates was determined by
the normalized percent signal intensity compared to the 100% value of PfPK7 autophosphorylation.

3.3 Results and Discussion
3.3.1 Verification of the Disruption of the PfPK7 Gene
The PfPK7- cell line was kindly provided by C. Doerig (Monash University, Clayton
Australia). This cell line was generated through the use of reverse genetics to disrupt the PfPK7
gene [27]. Briefly, PfPK7 was knocked out by utilizing a single crossover homologous
recombination to insert a corresponding central region of the PfPK7 catalytic domain next to a
domain conferring blasticidin resistance in the pCAM-BSD vector and transferred into 3D7
parasites through electroporation [45, 140]. The homologous recombination at the PfPK7 locus
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resulted in a pseudo-diploid configuration with two truncated copies of PfPK7 lacking essential
regions of the catalytic domain and disrupting the ability of PfPK7 to function properly [27].
To verify that the PfPK7- cell line had lost the wild type gene, we used both PCR and
Southern blot analysis. Either 50ng or 25ng of genomic DNA was used to detect a partial PfPK7
product (702 base pairs) similar to the genotype characterization carried out in the creation of the
PfPK7- cell line [27]. PCR analysis showed that the 3D7 wild type cell line contained the expected
702 base pair product (lanes 1 & 3) and that the PfPK7- cell line had lost the wild type PfPK7 gene
(lanes 2 & 4) (Fig. 18A).
As can be seen from Fig. 18C, a hybridization signal corresponding to pfpk7 was obtained
only in the genomic DNA isolated from the 3D7 wild type cell line when using the PfPK7 probe.
Fig. 18B demonstrates equal loading of digested genomic DNA for both wild-type 3D7 and PfPK7-.
Taken together, the PCR and Southern blot analysis confirms the lack of full-length PfPK7 in the
PfPK7- cell line; however, PfPK7 is still present and functional in the wild-type 3D7 cell line.

3.3.2 Identification of 1,047 Phosphoproteins and 3,875 Phosphorylation Sites from the Schizont
and Segmenter Intraerythrocytic Stages of Plasmodium falciparum
We used isobaric labeling for quantitative analysis of LysC-digested parasite extracts
prepared from tightly synchronized schizont (approximately 36 hours ± 4 hours post-invasion) and
segmenter (approximately 46 hours ± 4 hours post-invasion) stages. Fig. 19 depicts representative
images of the wild type 3D7 cultures (Fig. 19A) and PfPK7- cultures (Fig. 19B) harvested at each
of the cell cycle stages. A workflow depicting the phosphoproteomic analysis is outlined in Fig. 20.
This quantitative phosphoproteomic analysis identified a total of 1,047 proteins and 6,795
phosphorylation sites across both cell lines and both intraerythrocytic cell cycle stages. Of these
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phosphorylation events, only 3,875 met our strict quantification standards at a protein-level FDR of
<1%.
In addition to identification, we also provided quantitative analysis of phosphorylation
changes comparing the two cell lines at the schizont and segmenter stages. To determine which
phosphorylation events were occurring predominately in the 3D7 wild type cell line, the PfPK7- cell
line, or equally in both cell lines, we examined each phosphorylation site to define those with a
>1.5- fold increase or decrease between the cell lines. Phosphorylation events exhibiting greater
than a 1.5-fold difference in abundance between the two were considered to be enriched in that
particular cell line, while phosphorylation events showing less than a 1.5-fold change between the
two cell lines were considered to be present equally in both the wild type 3D7 and PfPK7-. Fig. 21A
demonstrates the distribution of phosphorylation events for each of the cell lines. At the schizont
stage, a total of 1,490 phosphorylation events were classified as occurring in the 3D7 wild type cell
line, which means that these phosphorylation events exhibited a greater than 1.5-fold decrease in
phosphorylation when PfPK7 was no longer functional. Furthermore, 609 phosphorylation events
were classified as 3D7 at the segmenter stage. Interestingly, 794 phosphorylation events at the
schizont stage and 1,027 phosphorylation events at the segmenter stage were up regulated in the
absence of PfPK7 (Fig. 21A). The increase in phosphorylation seen on some proteins that occurs in
the absence of PfPK7 could possibly be a compensatory mechanism the parasite is utilizing to
ensure survival in the absence of PfPK7. Further analysis across the cell lines revealed that
approximately 41% of the schizont stage phosphorylation events and 58% of the segmenter
phosphorylation events were detected equally in both cell lines, while 20.5% of the phosphorylation
events at the schizont stage and 26.5% of the phosphorylation events at the segmenter stage have
decreased phosphorylation in the absence of a functional PfPK7 (Fig. 21B).
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3.3.3 Analysis of Decreased Phosphorylation Events and the Identification of Unique
Phosphorylation Motifs
To analyze phosphorylation events that may be occurring due to PfPK7 activity, we
examined the phosphoproteomic data for proteins with a greater than 1.5-fold decrease in
phosphorylation in both the schizont and segmenter stages in the absence of PfPK7. A total of 239
phosphorylation events on 146 phosphoproteins exhibited decreased phosphorylation at both
intraerythrocytic stages (Fig. 22A). The five phosphoproteins with the biggest decrease in
phosphorylation at the schizont and segmenter stages are shown in Table 2A and Table 2B,
respectively.
We sorted proteins into functional classes using the Munich Information Centre for Protein
Sequences (MIPS) catalog with some adaptations for classes specific to the Plasmodium parasite,
such as proteins pertaining to malaria pathogenesis [1, 110]. Functional classification was carried
out on the entire phosphoproteomic data set, which was then compared to the functional
classification of the 146 phosphoproteins with decreased phosphorylation in the absence of PfPK7
at both the schizont and segmenter stages. The distribution of the functional profiles is summarized
in Fig. 22B. The comparison of functional profiles did not result in any marked differences (Fig.
22B). For example, 3% of the phosphoproteins from the overall data set and 3% of the
phosphoproteins with decreased phosphorylation at both intraerythrocytic stages in the absence of
PfPK7 are involved in the cell cycle and DNA processing category. This demonstrates that in the
absence of PfPK7, no single functional category is dramatically affected. More specifically, this
indicates that PfPK7 does not specifically phosphorylate proteins within a given functional
category; if so, we would have detected a significant decrease in the percentage of proteins in that
particular functional category when comparing the functional profiles.
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To further investigate the involvement of PfPK7 in phosphorylating proteins at the schizont
and segmenter stages, we compared the phosphorylated peptides in the overall data set to those with
decreased phosphorylation in the absence of PfPK7 at both of these stages. MotifX analysis was
performed to identify primary sequence motifs directly or indirectly associated with PfPK7 activity.
Three motifs were identified that are enriched among pS sites in Plasmodium falciparum that were
down regulated (Fig. 22C). When compared to the entire data set, the RxxS* motif had the greatest
fold increase (4.12-fold) in the proteins with decreased phosphorylation when PfPK7 was no longer
functional. The RxxS* motif is a well-known phosphorylation motif matching the AGC-family of
kinases, which includes members such as cAMP-dependent protein kinase (PKA), cGMPdependent protein kinase (PKG), protein kinase C, AKT, and RSK. This class of kinases recognizes
an Arg at position -3 relative to the phosphorylated residue [141, 142]. Akt has been shown to play
a central role in the mediation of cellular processes such as cell growth and survival and
transcriptional regulation [143]. The fact that PfPK7 functions similarly to AKT by regulating cell
proliferation and also recognizes the RxxS* motif supports the idea that PfPK7 may have a role in
regulating cell growth and proliferation of Plasmodium.
The MotifX analysis also identified a greater than 3-fold enrichment of the S*xD and
RxxxxxS* motifs among the proteins with decreased phosphorylation at both the schizont and
segmenter stages in the absence of PfPK7 (Fig. 22C). The S*xD motif is traditionally utilized by
casein kinase 1 (CK1) and casein kinase 2 (CK2), while the RxxxxxS* motif is commonly
recognized by protein kinase C (PKC) or CDC2-like kinase (CLK2). The CK1 and CK2 protein
kinase families are serine/threonine protein kinases, which have been evolutionarily conserved
through many species [144]. Members of the CK1 family function as regulators of signal
transduction pathways in many eukaryotic cells. These kinases are responsible for phosphorylating
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substrates involved as key regulatory proteins in the control of cell differentiation, proliferation, and
chromosome segregation [144]. Members of the CK2 family of protein kinases have functions
similar to CK1 members and have been shown to have involvement in cell cycle control, DNA
repair, and regulation of circadian rhythm of cellular processes [145]. The CLKs are an
evolutionarily conserved group of dual specificity kinases belonging to the CMGC group of
kinases. The CLK family of protein kinases interact and/or phosphorylate serine/arginine-rich (SR)
proteins of the spliceosomal complex. CLK2 is involved in the regulation of several cellular
processes including cell cycle progression [146, 147]. PfPK7’s ability to phosphorylate proteins
with motifs traditionally recognized by AKT, CK1, CK2, and CLK2 supports the role of PfPK7 in
cell cycle control and cell proliferation.

3.3.4 Identification and Characterization of Putative PfPK7 Substrates
In an effort to identify putative substrates of PfPK7, we examined all of the phosphorylation
sites displaying decreased phosphorylation at both the schizont and segmenter stages in the absence
of PfPK7. A total of 146 phosphoproteins fit this criteria and these proteins may represent putative
substrates of PfPK7. The phosphoproteins with the largest decrease in phosphorylation at both
intraerythrocytic stages are more likely to be true substrates of PfPK7 than those with only small
decreases in phosphorylation. After examining the phosphoproteins with decreased phosphorylation
in the absence of PfPK7, we generated His-tagged recombinant forms of the six proteins with the
largest decrease in phosphorylation at both asexual stages. Table 3A displays the cloned proteins as
well as the phosphorylated peptides that exhibited a significant decrease in phosphorylation, the
biological process the protein is involved in, and it’s molecular function. Next, we identified the
three phosphorylation events occurring at an RxxS* motif with the largest decrease in
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phosphorylation and a recombinant His-tagged form of these proteins were generated. Table 3B
shows the recombinant proteins as well as the phosphorylated peptide, the biological process the
protein is involved in, and the protein’s molecular function. The phosphorylated peptides were then
subjected to motif analysis in order to predict the protein kinase that may be responsible for the
phosphorylation event. Significantly, the majority of phosphorylated peptides with large decreases
in phosphorylation in the absence of PfPK7 are predicted to be recognized by CK1, CK2, and AKT
(Table 3A and 3B). This prediction and the fact that motifs recognized by CK1, CK2, and AKT
kinases are enriched among phosphopeptides with decreased phosphorylation when PfPK7 is
absent, suggests the functional similarities of PfPK7 to CK1, CK2, and AKT protein kinases.
Alternatively, PfPK7 may act upstream of PfCK1, PfCK2, and PfAKT, thus regulating their
downstream activities.
In order to better define the role of PfPK7 in Plasmodium falciparum we performed in vitro
kinase assays to test that identified substrates are utilized by the kinase. Fig. 23A and 23C show 1μg
of recombinant PfPK7 and 5μg of recombinant substrate were used for each assay condition. After
five independent kinase assays, it was clear that PfPK7 was able to robustly phosphorylate a
conserved Plasmodium protein (PF10_0257) compared to the generic substrate myelin basic protein
(MBP) (Fig. 23B). PfPK7 was also able to directly phosphorylate 60s ribosomal protein
L7Ae/L30e, putative (PFD0960c) and a conserved Plasmodium protein (PFB0490c) to a lesser
extent (Fig. 23D). The ability of PfPK7 to phosphorylate these substrates was determined by
normalizing signal intensity values to the master mix alone (0% value) and PfPK7 autophosphorylation (100% value). PfPK7 phosphorylation of PF10_0257 was 59%, which is greater
than PfPK7’s phosphorylation of the control substrate MBP at 38% (Fig. 23E). PfPK7’s
phosphorylation of PFD0960c and PFB0490c was 7% and 7%, respectively (Fig. 23E). Although
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PFD0960c and PFB0490c were not phosphorylated as much as was detected for PFB0490c, all
three of these proteins were directly phosphorylated by PfPK7 to some extent.

3.3.5 Revealing the Role of PfPK7 in Plasmodium falciparum Signaling Pathways
It was interesting to note that PfPK7 was only able to directly phosphorylate three of the
tested potential substrates and was not able to directly phosphorylate four of the tested potential
substrates. Out of the three phosphorylated proteins, two contained the S*xD motif and one
contained the RxxS* motif. The ability of PfPK7 to utilize the RxxS* motif was tested by
determining the ability of PfPK7 to phosphorylate four different proteins containing this motif and
only one was phosphorylated, suggesting that PfPK7 does not directly recognize the RxxS*
phosphorylation motif and instead may be utilizing the S*xD motif. Further supporting PfPK7’s use
of the S*xD phosphorylation motif is the fact that the substrate with the most robust
phosphorylation (PF10_0257) contained this motif. Due to the inability of PfPK7 to directly
phosphorylate all of the proteins identified with decreased phosphorylation in Plasmodium
falciparum when PfPK7 was absent, it is likely that PfPK7 may act as an upstream regulatory
kinase responsible for phosphorylating intermediary kinases. One avenue that needs to be
investigated further is whether PfCK1, PfCK2, PfPKB (Plasmodium falciparum homologue of
AKT), or PfPK2 (Plasmodium falciparum homologue of CLK2) are the intermediary kinases,
activated when phosphorylated by PfPK7, which then phosphorylate the proteins detected in the
phosphoproteomic analysis displaying decreased phosphorylation in the absence of PfPK7. PfCK1,
PfCK2, PfPKB, and PfPK2 are likely candidates of intermediary kinases in the PfPK7 signaling
cascade due to the fact that the RxxS* phosphorylation motif recognized by these kinases are
significantly enriched among the 239 decreased phosphorylation events detected in the absence of
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PfPK7; however, PfPK7 does not seem to directly phosphorylate this motif. Furthermore, PfCK1,
PfCK2, and PfPKB are expected to have a role in the PfPK7 signaling pathway because the
phosphorylated peptides with the largest decreases in phosphorylation when PfPK7 is no longer
present are predicted to be phosphorylated by PfCK1, PfCK2, and PfPKB. The potential regulatory
role of PfPK7 phosphorylation in a signaling cascade is depicted in Fig. 24.

3.4 Conclusions
A major challenge in understanding the noncanonical nature of the Plasmodium falciparum
cell cycle is the fact that nothing is currently known about malaria signaling cascades. In depth
analysis of the molecular switches governing intraerythrocytic cell cycle progression is needed; and
characterizing the protein kinases and their substrates involved in this process is crucial. However, a
significant obstacle in defining cellular signaling networks is to establish physiological kinasesubstrate relationships. Many Plasmodium protein kinases are atypical, possessing hybrid features,
marking them as unique Plasmodium-specific targets for therapeutic intervention. This kinase
negative phosphoproteomic study identified 146 proteins with decreased phosphorylation at the
schizont and segmenter stages in the absence of PfPK7, suggesting the role of PfPK7 in their
phosphorylation. Although phosphoproteome profiling may provide clues to substrate
identification, establishing direct kinase substrate relationships require activity-based assays. Our
analysis also supports this statement because of the identified potential substrates, PfPK7 was only
able to directly phosphorylate three of the tested proteins. Furthermore, of the three phosphorylation
motifs that are enriched among phosphorylated sites in Plasmodium proteins that were down
regulated, the S*xD motif is present in two of the substrates. The inability of PfPK7 to directly
phosphorylate all of the phosphoproteins that displayed decreased phosphorylation in the absence of
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PfPK7, suggests a role of PfPK7 as an upstream regulatory kinase. Our phosphoproteomic analysis
of the PfPK7 kinase deficient cell line highlights the limitations of this approach because it is
difficult to ascertain if a change in protein phosphorylation is a direct effect due to the loss of
PfPK7 or the orchestration of events of a signaling cascade. Although it is beyond the scope of this
work, a recently developed approach to experimentally determine kinase-substrate pairs through the
integration of data obtained from phosphorylation reactions on protein microarrays, bioinformatics,
and phosphoproteomics [148] would possibly be a better approach to generate a high resolution
signaling network. Nevertheless, our data defines the proteomics landscape in Plasmodium whose
phosphorylation is affected due to the loss of PfPK7 function and is a step towards better
understanding the mechanism of cellular signaling in the parasite.
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Figure 17: Verification of the Presence of PfPK7 in the Wild Type 3D7 Cell Line and the
Absence of PfPK7 in the PfPK7- Cell Line
(A) PCR analysis to verify the presence or absence of PfPK7 in the representative cell lines. The
PCR analysis was performed with 25ng and 50ng of genomic DNA for both cell lines. (B) One
microgram of digested 3D7 and PfPK7- genomic DNA was run on a 0.8% agarose gel. The image
demonstrates equal loading of DNA for the two cell lines prior to transfer to the Nytran SPC
membrane. (C) Autoradiogram of the Southern blot analysis performed using a full length PfPK7
probe against the wild type 3D7 cell line and the PfPK7- cell line.
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Figure 18: Representative Images of 3D7 Wild Type and PfPK7- Time Points Harvested for
Phosphoproteomic Analysis
Geimsa stained images of the cultures harvested for the two cell lines at the two stated
intraerythrocytic stages. (A) Representative images of the schizont and segmenter stage parasites
harvested for the wild type 3D7 cell line. (B) Representative images of the schizont and segmenter
stage parasites harvested for the PfPK7- cell line.
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Figure 19: Overview of the Procedure for Phosphopeptide Preparation and Analysis
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Duplicate samples from each time point for each cell line were pooled and processed to generate the
lists of phosphorylation sites. Protein samples were digested with LysC, labeled with TMT,
fractionated on a SCX column, and enriched for phosphopeptides using IMAC. The resulting
phosphopeptide samples were analyzed on an LTQ-Velos Oribtrap mass spectrometer. SEQUEST
was used to identify spectra and the data was filtered to a protein-level false discovery rate of 1%.
Phosphorylation site localization was analyzed through AScore and phosphorylation sites with an
AScore above 13 were considered to be localized. Phosphorylation sites with a greater than1.5-fold
decrease at both stages were classified as potential PfPK7 substrates and MotifX analysis was
performed. After potential PfPK7 substrates were cloned, in vitro kinase assays were performed to
test the ability of PfPK7 to phosphorylate the substrates.
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Figure 20: Identification of the Phosphoproteome from the Schizont and Segmenter
Intraerythrocytic Stages in the Presence and Absence of PfPK7
(A) The table depicts the number of phosphorylation events that were classified as belonging to
each cell line. The phosphorylation events that did not display greater than a 1.5-fold change
between cell lines were classified as both lines. Three phosphorylation events that were detected in
the schizont stage were not detected in the segmenter stage; therefore, there were only 3,872
phosphorylation events detected at this stage. (B) Number of phosphorylation sites classified at the
schizont and segmenter stages for the wild type 3D7 cell line, PfPK7- cell line, and both cell lines.
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Figure 21: Examination of Decreased Phosphorylation Events in the PfPK7- Cell Line
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(A) A total of 1,490 phosphorylation events were decreased at the schizont stage, 609 were
decreased at the segmenter stage, and 239 were decreased in the PfPK7- cell line at both stages
when compared to the wild type. (B) Functional profiles of identified proteins using GO
annotations downloaded from PlasmoDB (www.plasmodb.org) or UniProt (www.uniprot.org) as
defined by the MIPS catalogue. To avoid redundancy, we assigned only one class per protein. A
comparison of the percentage of proteins in each functional group in the overall phosphoproteomic
data set compared to the proteins identified with decreased phosphorylation in the absence of
PfPK7. The comparison shows that both data sets had the same relative distribution of proteins in
each of the functional categories. (C) MotifX analysis was performed to compare the
phosphorylation peptides in the overall data set to those with decreased phosphorylation in the
absence of PfPK7. Three motifs were identified that are enriched among pS sites in Plasmodium
falciparum that were down-regulated. When compared to the entire data set, the RxxS* motif had
the best fold increase (4.12-fold) in the proteins with decreased phosphorylation when PfPK7 was
knocked out.
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Table 2: Quantification of the Top Five Decreased Phosphorylation Events in the PfPK7- Cell
Line
Table 2A: Quantification of the Top Five Decreased Phosphorylation Events in the PfPK7Cell Line at the Schizont Stage
PfPK7-

3D7 Wild Type
Accession
Number

C6KT20

Q8IC01
Q9TY99
Q8I5E2
Q8IDF2

Annotation

Site

Motif Peptide

Schizont
Score

Segmenter
Score

Schizont
Score

Segmenter
Score

Schizont
Comparison

Segmenter
Comparison

Conserved
Plasmodium
Membrane
Protein

S489

YLKDKKSLILEKK

244.08

1300.64

5.80

784.94

0.02377

0.60349

Cg4 Protein
Knob-associated
Histidine-Rich
Protein
Cyclin Related
Protein
Conserved
Plasmodium
Protein

T863

EEKENSTKNENSA

91.53

394.09

2.37

90.28

0.02593

0.22909

EATKEASTSKEAT

6.95

1278.25

0.195

398.84

0.02799

0.31202

S688

VKNDLESEKGRGR

114.56

580.33

4.39

126.73

0.03838

0.21837

S193

PKNLQHSDNEKNQ

199.88

618.91

7.72

129.03

0.03860

0.20847

S558

Table 2B: Quantification of the Top Five Decreased Phosphorylation Events in the PfPK7Cell Line at the Segmenter Stage
-

3D7 Wild Type
Accession
Number

Annotation

Site

Motif Peptide

Schizont
Score

C6KT82

Smarca-Related
Protein

S1327

DDDDDNSVDAKYN

127.64

11.46

Q8IBZ5

Cg7 Protein

S171

KNKNLSSYEEKKL

418.79

183.79

ELFDGKSEEWEEK

872.13

73.64

S2073

ISNNNKSISSNNK

482.59

S1049

NDGDNKSQEDDDG

67.78

Q8IFM2

Q8IID3
O77384

SurfaceAssociated
Interspersed
Gene 4.2
Myb-like DNAbinding Domain
Conserved
Plasmodium
Protein

S1395

Segmenter
Score

PfPK7
Schizont
Score

Segmenter
Score

Schizont
Comparison

15.87

0

0.12431

0

218.22

13.30

0.52108

0.07236

236.55

10.13

0.27123

0.13761

1251.63

41.47

202.91

0.08592

0.16212

297.39

11.13

49.79

0.16414

0.16742

Segmenter
Comparison

(A) The top five phosphorylation events exhibiting a greater than 1.5-fold difference between the
wild type 3D7 cell line and the PfPK7- cell line at the schizont stage. The representative
phosphorylation events displayed the largest decrease in phosphorylation in the absence of PfPK7
at the schizont stage. The columns corresponding to the schizont and segmenter scores for the 3D7
wild type and PfPK7- cell lines are the normalized intensities associated with each particular stage.
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(B) The top five phosphorylation events exhibiting a greater than 1.5-fold difference between the
wild type 3D7 cell line and the PfPK7- cell line at the segmenter stage. The representative
phosphorylation events displayed the largest decrease in phosphorylation in the absence of PfPK7
at the segmenter stage. The columns corresponding to the schizont and segmenter scores for the
3D7 wild type and PfPK7- cell lines are the normalized intensities associated with each particular
stage.
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Table 3: Identification of Putative PfPK7 Substrates
Table 3A: Identification of Putative PfPK7 Substrates

Table 3B: Identification of Putative PfPK7 Substrates with the RxxS* Motifs
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(A) The top six proteins exhibiting the largest decrease in phosphorylation in the PfPK7- cell line
when compared to the wild type 3D7 cell line at the schizont and segmenter stages. The
phosphorylated peptide was analyzed using GPS 3.0 (Group-based Prediction System) to predict
the kinase/s that may be responsible for the phosphorylation event. The columns also describe the
biological process and molecular function of the phosphorylated protein as stated using GO term
analysis. (B) The top three proteins exhibiting the largest decrease in phosphorylation at a peptide
containing the RxxS* motif in the PfPK7- cell line when compared to the wild type 3D7 cell line at
the schizont and segmenter stages. The phosphorylated peptide was analyzed using GPS 3.0 to
predict the kinase/s that may be responsible for the phosphorylation event.
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Figure 22: Validation of Putative PfPK7 Substrates
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(A) Coomassie blue stained gel of the in vitro kinase assays. Lane 1: Master mix, Lane 2: MBP,
Lane 3: PfPK7, Lane 4: PfPK7 + MBP, Lane 5: PF10_0257, Lane 6: PfPK7 + PF10_0257, Lane 7:
PF14_0068, Lane 8: PfPK7 + PF14_0068, Lane 9: PF10_0068, Lane 10: PfPK7 + PF10_0068. (B)
Phosphoimage of the in vitro kinase assay gel depicted in (A). (C) Coomassie blue stained gel of
the in vitro kinase assays. Lane 1: PFD0960c, Lane 2: PfPK7 + PFD0960c, Lane 3: PFI1555w,
Lane 4: PfPK7 + PFI1555w, Lane 5: PF13_0102, Lane 6: PfPK7 + PF13_0102, Lane 7: PFB0490c,
Lane 8: PfPK7 + PFB0490c, Lane 9: PF14_0190, Lane 10: PfPK7 + PF14_0190. (D)
Phosphoimage of the in vitro kinase assay gel depicted (C). (E) Normalized signal intensity values.
Master mix alone was set as the 0% value and PfPK7 auto-phosphorylation was set as the 100%
value.
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Figure 23: PfPK7's Potential Regulatory Role in Plasmodium Signaling Networks
Schematic representation of PfPK7’s potential regulatory role in Plasmodium. Protein kinases are
depicted in blue, proteins containing the S*xD motif are purple, proteins containing the RxxS*
motif are green, and proteins containing the RxxxxxS* motif are orange. PfPK7 directly
phosphorylates PF10_0257, PFD0960c, and PFB0490c. PfPK7 may act as an upstream regulatory
kinase, phosphorylating PfCK1, PfCK2, PfPKB, PfPKC, and/or PfPK2 activating these kinases
through phosphorylation (shown with dashed lines). The activated kinase/s may then phosphorylate
the proteins identified with decreased phosphorylation when PfPK7 was absent.
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CHAPTER 4: ELUCIDATING THE FUNCTIONS OF PLASMODIUM
FALCIPARUM PROETIN KINASES THROUGH
SUBSTRATE/INTERACTOR CHARACTERIZATION
4.1 Summary
The life cycle of the malaria parasite is complex and oscillates between stages of intense cell
proliferation and stages where the cell withdraws from proliferation. It is expected that members of
cyclin-dependent kinases and other protein kinases function as key regulators of the Plasmodium
cell division stages, similarly to other eukaryotes. Although a number of Plasmodium protein
kinases, including CDKs, have been identified, very little is known about their precise physiological
functions. For a better understanding of the protein kinases that regulate the intraerythrocytic
developmental cycles of Plasmodium we recently reported comprehensive isobaric-tag based
quantitative proteomics and phosphoproteomics analyses. This study identified 43 distinct
phosphorylation motifs and a range of proline-directed potential MAPK/CDK substrates.
Additionally, to identifying substrates and interactors of Plasmodium CDK-like kinases, we have
used HA-tagged PfPK6 and Pfmrk cell lines where endogenous protein kinase loci were replaced
with epitope-tagged genes by homologous recombination. Using co-immunoprecipitation of the
HA-tagged PfPK6 and Pfmrk baits with highly specific anti-HA antibody cross-linked to agarose
beads, followed by mass spectrometric analyses of tryptic peptides, we have identified the
components of the protein interaction complexes of these kinases. To eliminate non-specific
interactions we have developed a novel filtering system based on Shannon entropy, using the
number of spectral counts observed in a pair of replicates. The validity of our scoring system is
underscored by the identification of Pfcyc-1 and PfMAT1 as specific interactors of Pfmrk, which
have been previously reported. Our analyses of HA-PfPK6 and HA-Pfmrk immunoprecipitates have
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identified 15 and 21 proteins in the interaction complex, respectively. Among the proteins identified
in the PfPK6 interaction complex are many with nuclear roles e.g. Nucleolar GTP-binding protein 1
(PFF0625w) and an uncharacterized protein (MAL8P1.127) with a role in mRNA processing and
RNA splicing. Components of the Pfmrk interaction complex appear to contain proteins with
diverse functions such as a DNA excision-repair helicase homolog (PFI1650w) and a
methyltransferase (PF07_0015). The ability of recombinant PfPK6 to interact and/or utilize any of
the proteins identified in the interaction complex as substrates revealed the ability of PfPK6 to
directly phosphorylate a regulator of chromosome condensation, putative (MAL7P1.38).
Furthermore, site-directed mutagenesis of PfPK6 demonstrated the necessity of the residue T178 in
the T-loop for activation of PfPK6 through auto-phosphorylation in order for PfPK6 to
phosphorylate its substrates.

4.2 Materials and Methods
4.2.1 Plasmodium falciparum Culture
The HA-tagged PfPK6 and Pfmrk cell lines were kindly provided by C. Doerig (Monash
University, Clayton Australia). Parasites of Plasmodium falciparum strain 3D7 with either HAtagged PfPK6, HA-tagged Pfmrk, or wild type 3D7 were grown at a 4-10% parastemia and 4%
hematocrit in RPMI 1640 culture medium supplemented with A+ erythrocytes and 0.5% albumax
as previously described [88]. Blasticidin was added to a final concentration of 2.5μg/ml in the HAtagged cultures.
Parasite growth and parastemia were periodically monitored by Giemsa-stained blood
smears. Once parastemia reached 10%, parasites were harvested from 120 plates for each cell line
following established protocols [91]. Parasites were isolated by lysing the red blood cells in 0.1%
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saponin followed by thorough washing in PBS. The subsequent parasite pellets were weighed and
proteins were immediately extracted by lysis in an 8M urea lysis buffer supplemented with protease
inhibitors (8M urea, 75mM Tris, pH 8.2, 1X HALT protease inhibitor, 1X HALT phosphatase
inhibitor) [16]. Lysates were cleared by centrifugation for 10 minutes at 4°C at 14,000 rpm. Protein
concentration was determined for each sample by BioRad Bradford Assay.

4.2.2 Previous Global Phosphoproteomic Analysis Identifies Putative MAPK/CDK Substrates
Our previous global phosphoproteomics analysis was used to identify putative MAPK/CDK
substrates. The analysis was performed as described previously [1]. Equal quantities of duplicate
protein extracts (1mg) from each of the three intraerythrocytic P. falciparum stages were reduced,
alkylated, and digested with Lys-C prior to labeling with one of 6 TMT isobaric labeling reagents
[87]. All 6 samples were then mixed together and separated via strong cation exchange
chromatography and a total of 20 fractions were collected. The resulting 20 fractions were subjected
to IMAC to specifically isolate phosphorylated peptides [92]. Phosphopeptides were analyzed via
LC-MS/MS on an LTQ-Orbitrap-Velos mass spectrometer essentially as described previously [93],
except that all MS/MS spectra were acquired at high resolution in the Orbitrap and used for both
phosphopeptide identification and quantification. Peptides were identified by matching individual
MS/MS spectra with peptide sequences using Sequest [94]. As before, searches employed a
database containing Plasmodium sequences from NCBI [96] as well as human protein sequences
from IPI [97]. The peptides were filtered using a multivariate approach to remove questionable
identifications based on a target-decoy strategy [95, 98]. Peptides were assembled into proteins and
proteins were further filtered to ensure a protein-level false discovery rate of 1%. Individual
phosphorylation sites on each peptide were scored to assess how confidently the modification could
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be localized to a single residue using AScore [99]. Finally, the peptides and proteins were filtered to
account for protein redundancy.
To identify putative MAPK/CDK substrates, all phosphorylation events identified in the
global phosphoproteomic analyses were examined for the presence of the proline-directed Ser/Thr
phosphorylated peptides. The 206 identified peptides were then filtered further to recognize only
those containing the strong CDK consensus pS/T-P-X-K/R motif, which revealed 45 proteins that
are putative Plasmodium CDK substrates. Another method used to identify putative MAPK/CDK
substrates was immunoprecipitation with PTMScan® Direct. PTMScan® Direct allows for the
isolation of proteins containing post-translational modifications; more specifically, in this study, the
isolation of proteins that are phosphorylated at the strong CDK consensus sequence. The
PTMScan® Direct protocol was adapted from the PhosphoScan® method developed at Cell
Signaling Technology with licensed use [100]. The protocol used for the PTMScan®
Immunoprecipitation procedure was followed as previously described [1].

4.2.3 Potential Substrate Expression Constructs, Recombinant Protein Expression, and
Purification
After analyzing the global phosphoproteomic data and performing PTMScan® Direct we
identified a number of putative MAPK/CDK substrates. In order to investigate if any of these
proteins are in fact substrates of PfPK6, we generated His-tagged constructs of the potential
substrates. Due to the large size of many of the potential substrates, truncated versions of the
proteins containing putative phosphorylation site(s) were cloned. Each open reading frame (ORF)
was truncated to ~1500 base pairs while ensuring the presence of the phosphorylated peptide
containing the pS/T-P-X-K/R motif. The following proteins were cloned into the pET30 EK/LIC
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vector following the manufacturer’s instructions (EMD Millipore): MAL7P1.38, PFE0155w,
PF11_0332, PF10_0047, and PFC0805w. All ORFs were sequence confirmed prior to further use.
The potential substrates were optimally expressed in BL21-CodonPlus (RIPL) cells (Stratagene)
and purified from the soluble fraction by affinity chromatography using HisLink resin and
following the manufacturer’s instructions (Promega).

4.2.4 In vitro Kinase Assays
Kinase reactions to measure PfPK6 auto-phosphorylation and activity toward the potential
substrates were performed by using 1μg of recombinant PfPK6 and 5μg of recombinant substrate in
a total volume of 30μl as described previously [45, 139]. A standard kinase buffer containing
20mM Tris/HCl (pH 7.5), 20mM MgCl2, 2mM MnCl2, 10μM ATP, and 5μCi (γ-32P) was used.
Kinase reactions were incubated for 30 minutes at 30°C and stopped by the addition of 5X gel
loading buffer. The entire kinase reaction was loaded on a 12% SDS/polyacrylamide gel. The gels
were then stained with Coomassie blue stain, de-stained using a 30% methanol and 10% glacial
acetic acid solution, dried, and exposed for autoradiography. Signal intensity values were obtained
and normalized by using the kinase buffer control as the 0% value and PfPK6 phosphorylation of
histone as the 100% value. The ability of PfPK6 to phosphorylate potential substrates was
determined by the normalized percent signal intensity compared to the 100% value of PfPK6
phosphorylation of histone.

4.2.5 In vitro Kinase Assays to Determine Key Residues for PfPK6 Activity
Previous work in our lab used site-directed mutagenesis to investigate the role of key
residues within the T-loop for PfPK6’s activity. The T-loop of eukaryotic protein kinases is also
referred to as the activation loop. It is a flexible loop in close proximity to the catalytic loop
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contains a key residue that, once phosphorylated, activates the kinase. Previous work generated
T173A, T175A, and T178A mutated PfPK6 constructs to investigate the importance of these T-loop
residues in PfPK6’s activity. The T178D and T178E mutant constructs were generated to mimic
phosphorylation at residue 178. In this study, the recombinant PfPK6 mutants were tested for their
affect on PfPK6 auto-phosphorylation, phosphorylation of a control substrate histone, and
phosphorylation of a novel PfPK6 substrate identified through substrate predictions from our global
phosphoproteomics analysis described above. In vitro kinase assays were performed using wild
type PfPK6, T173A PfPK6, T175A PfPK6, T178A PfPK6, T178D PfPK6, and T178E PfPK6. The
kinase assays were performed as described above.

4.2.6 Western Blot Analysis
Plasmodium falciparum 3D7 strain parasites, HA-tagged PfPK6 parasites, and HA-tagged
Pfmrk parasites were harvested following established protocols once parastemia reached 10% [91].
Parasites were isolated by lysing the red blood cells in 0.1% saponin (w/v), followed by thorough
washing in PBS. The subsequent pellets were weighed and recorded. Proteins were immediately
extracted by lysis in an 8M urea lysis buffer supplemented with 1X HALT protease inhibitor (8M
urea, 75mM Tris, pH 8.2) and centrifuged for 10 minutes at 4°C at 14,000rpm. A BioRad Bradford
Assay was used to determine the protein concentrations of the cleared lysates. The protein lysates
were stored at -80°C until use.
For Western blotting, 100μg of protein extract from each cell line was loaded on a 12%
SDS-PAGE gel with protein running buffer and run at 100 volts for approximately 3 hours. After
electrophoresis, the gels were rinsed in transfer buffer (NuPAGE 1X Transfer Buffer) and
transferred onto nitrocellulose using the NuPAGE wet transfer module at 30 volts for 1 hour at 4°C
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according to the manufacturer’s instructions (Invitrogen). The membrane was blocked in 5% milk
in tris-buffered saline containing 0.1% Tween 20 for 1 hour at room temperature. The membrane
was then incubated with a 1:1000 dilution of goat anti-HA primary antibody overnight in 5% milk
tris-buffered saline containing 0.1% Tween 20 at 4°C. The membrane was washed 3 times for 10
minutes each in 5% milk tris-buffered saline containing 0.1% Tween 20. Next, the membrane was
incubated with horseradish peroxidase-conjugated secondary antibody at a 1:2000 dilution for 1.5
hours at room temperature, washed, and developed using enhanced chemiluminescence detection
according to the manufacturer’s instructions (Cell BioSciences).

4.2.7 Immunofluorescence Assays
Immunofluorescence assays were performed in order to confirm the presence of the HAtagged PfPK6 and Pfmrk as well as determine the proteins’ cellular localization. The following
immunofluorescence assay (IFA) procedure was used for both HA-tagged cell lines. A total of 3ml
of culture were harvested per IFA at 4% hematocrit and 7% parastemia by centrifuging at 1,500
rpm for 3 minutes at 4°C. Each sample was washed once in serum-free RPMI media and
centrifuged as before. The pellet was re-suspended in 1ml/ml of original culture fixation solution
(4% paraformaldehyde 0.0075% glutaraldehyde in 1X PBS, pH 7.4) and incubated at 37°C for 30
minutes with gentle mixing. The samples were washed with 1X PBS, pH 7.4 and centrifuged at
1,850rpm for 3 minutes at 4°C. The supernatant was removed and the pellet was re-suspended in
3ml of permeablization solution (0.1% Triton X 100 in 1 X PBS, pH 7.4), incubated for 10 minutes
at room temperature with gentle mixing, centrifuged, and washed as before. Next, the pellet was resuspended in 3ml of blocking solution (3% BSA in 1X PBS, pH 7.4), incubated for 1 hour at room
temperature with gentle mixing, centrifuged, and washed as before. After removal of the

111

supernatant, the pellet was re-suspended in 1ml of blocking solution containing the goat anti-HA
primary antibody at a 1:100 dilution. The sample was incubated overnight at 4°C with end-over-end
mixing. After centrifuging at 2,000 rpm for 2 minutes at 4°C, the pellet was washed 3 times for 10
minutes each in blocking solution. The pellet was then re-suspended in 1ml blocking solution
containing donkey anti goat 488 flurophore secondary antibody. From this point forward, the
samples were kept covered to prevent light exposure. Samples were incubated for 2 hours at room
temperature with end-over-end mixing, followed by washing as described before. The final pellet
was re-suspended in 500μl of 1X PBS, pH 7.4.
In order to prepare the coverslips and slides, the coverslips were dipped in 70% molecular
grade ethanol. The coverslips were placed on paper and allowed to air dry. Next, 300μl of 1mg/ml
poly-L-lysine was added to each coverslip and incubated for 15 minutes. The solution was removed
and coverslips air dried. Then, 200μl of 1X PBS pH 7.4 was added to the coverslip, 8μl of the
immunofluorescence assay was added to the PBS, and incubated for 15 minutes. The solution was
removed and the coverslip was air dried. To prepare the slide, 10μl of Dapi fluoromount was added
to the slide and the coverslip was placed cell side down onto the fluoromount. The slides were
stored in the dark for 24 hours prior to imaging via confocal microscopy.

4.2.8 Co-Immunoprecipitation to Identify Interacting Partners
The Pierce HA Tag IP/Co-IP kit from Thermo Scientific was used to isolate proteins that are
interacting with either PfPK6 or Pfmrk. The Co-immunoprecipitation procedure was carried out for
the wild type 3D7 cell line as a negative control and was also carried out on the experimental HAtagged PfPK6 and HA-tagged Pfmrk cell lines. The procedure provided by the manufacturer was
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followed with some modifications. The co-immunoprecipitation experiment for each cell line was
performed in duplicate and the resulting elutions were pooled.
The following procedure was completed in duplicate for each cell line. A positive control
was also performed. A total of 8 reactions were used: 2 for the 3D7 wild type control, 2 for the
positive control provided by the manufacturer, 2 for the HA-tagged PfPK6, and 2 for the HAtagged Pfmrk. A total of 4.6mg of protein was used for each of the experimental conditions as well
as the 3D7 control. For the positive control, 50ul of the HA-tagged positive control diluted in 150μl
of TBS was used. The appropriate amount of lysate or positive control was added to a plugged spin
column. The anti-HA agarose was thoroughly re-suspended prior to dispensing 20μl of resin into
each labeled spin column using a wide-bore pipette tip. The cap was then screwed on to seal each
column. The lysate plus anti-HA agarose was incubated with gentle end-over-end mixing overnight
at 4°C. During this time, the TBS plus 0.5% Tween-20 (TBS-T) wash solution was prepared. After
lysate incubation, the cap was loosened on the column and the bottom plug was removed. Each
column was placed in a collection tube and centrifuged for 10 seconds at 4°C. The flow-through
was saved for SDS-PAGE analysis.
A total of 500μl of TBS-T was added to each column. The cap and bottom plug were
replaced and the column was inverted three times to gently wash the agarose. After removing the
bottom plug and loosening the cap, the column was placed back in the collection tube and
centrifuged for 10 seconds at 4°C. The collected wash was saved for future analysis. The washing
steps were repeated two additional times for a total of three washes. To elute, the bottom plug and
cap were removed, the spin column was placed in a new collection tube, 10μl of elution buffer was
added to the HA-agarose, the cap was loosely screwed on and gently tapped to mix, and the spin
column was centrifuged for 10 seconds at 4°C. The elution steps were repeated two additional times
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and collected in the same collection tube for a total of 30μl of elution. The eluent was immediately
neutralized by adding 1μl of 1M Tris, pH 9.5 per 20μl of elution buffer.
In order to perform mass spectrometry analysis on the co-immunoprecipitation eluent, we
resolved 10% of the eluted sample on an SDS-PAGE gel to verify the presence of sufficient
proteins for subsequent detection. The eluents from duplicate experiments were pooled for a total
volume of 60μl per condition; therefore, 6μl of eluent was run on an SDS-PAGE gel for each
condition. After the gel was run to completion, each gel was silver stained to detect the presence of
protein. First, each gel was placed in a clean staining tray and rinsed for 5 minutes with ultrapure
water. The gels were fixed overnight in 100ml fixative solution (40% ethanol and 10% acetic acid)
with gentle rotation. After decanting the fixative solution, gels were washed in 30% ethanol for 10
minutes. The ethanol solution was decanted and gels were incubated in 100ml of sensitizing
solution (0.02% sodium thiosulfate) for 10 minutes. The sensitizing solution was removed and the
gels were washed again in 30% ethanol for 10 minutes, followed by washing for 10 minutes in
ultrapure water. Next, the gels were incubated in 100ml of staining solution (0.1% silver nitrate) for
15 minutes. After removing the staining solution, gels were rinsed for 30 seconds in ultrapure
water. Each gel was then incubated in 100ml of developing solution (2% sodium carbonate and
0.04% formalin (37% formaldehyde)) for 4-8 minutes until bands appeared and the desired band
intensity is reached. Once the appropriate intensity is achieved, 10ml of stopper solution (5%
glacial acetic acid) was immediately added directly to the gel immersed in developing solution.
After being incubated for 10 minutes, the solution was decanted, the gel was washed for 10 minutes
with ultrapure water, and the gel was imaged. Once the presence of protein was confirmed in the
elution for the HA-tagged PfPK6 and HA-tagged Pfmrk co-immunoprecipitation experiments and
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the lack of protein in the elution for the 3D7 wild type control, the remaining eluent for each was
analyzed by mass spectrometry analysis.

4.2.8.1 Original Scoring System Eliminates Non-Specific Interactions
In order to identify true interacting partners of PfPK6 and Pfmrk while eliminating nonspecific interactors, a novel scoring system was generated based on the spectral counts obtained and
Shannon entropy. Two scores were calculated for each protein identified by mass spectrometry.
The first score was the Shannon entropy, which is based on the number of spectral counts observed
in a pair of replicates. To calculate the first score, 0.5 was added to spectral counts for both replicate
1 and replicate 2 spectral counts (because the entropy score is undefined when the value is zero).
Then the fraction of spectral counts observed in each replicate was calculated. For calculations,
rep1 = replicate 1 and rep2 = replicate 2
P1= (rep1 + 0.5) / (rep1 + rep2 + 1)
P2= (rep2 + 0.5) / (rep1 + rep2 + 1)
Next the entropy is calculated using the following formula:
Entropy= -1 * (P1 * Log2 (P1) + P2 * Log2 (P2))
An example for protein PF10_0141 is below:
P1= 27.5 / (27.5 + 15.5)
P2= 15.5 / (27.5 + 15.5)
Entropy = 0.943069
For score 1, the larger values imply that spectra are consistent between replicates for a given
protein. The cutoff value for score 1 was set to 0.75. Score 2 was calculated by taking the average
spectral counts for each protein across replicates, for each bait.
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Average= (rep1 + rep2)
An example for protein PF10_0141 is below:
Average 1 was calculated from the Pfmrk IP and average 2 was calculated from the control
3D7 IP.
Average 1= (27.5 + 15.5) / 2 = 21.5
Average 2= (0.5+0.5) / 2 = 0.5
Next the entropy was calculated using the formula discussed above:
Entropy 1 = 21.5 / (21.5 + 0.5) = 0.976
Entropy 2 = 0.5 / (21.5 + 0.5) = 0.023
For score 2, we attempted to find proteins whose spectral counts were skewed between the two
conditions rather than evenly distributed between the experimental and control samples, indicating
a search for smaller values. A cutoff of 0.6 was set for score 2.
Overall, a protein was called an interactor if it met 3 conditions: 1) Score 1 entropy > 0.75,
implying even expression between replicates for the IP, 2) Score 2 entropy < 0.6, implying skewed
expression when comparing the IP with the control, and 3) the average spectral counts for the IP
were greater than the average spectral counts in the control. This scoring system was validated by
the identification of two known interactors of Pfmrk, CDK-activating kinase assembly factor,
putative MAT-1 like protein (PFE0610c) and Cyclin 1 homologue (PF14_0605). The identification
of these two known interactors of Pfmrk validated this novel scoring system and allowed it to be
used to identify novel interacting partners of both Pfmrk and PfPK6.

116

4.2.9 Over Expression of Recombinant Interactors Using TnT SP6 Wheat Germ Expression
System
In order to confirm the interactions of PfPK6 with the proteins identified by coimmunoprecipitation we first expressed the proteins using the Promega TnT SP6 High-Yield Wheat
Germ Expression System. The TnT system couples transcription and translation in order to express
the proteins of interest. The six proteins with the strongest interaction with PfPK6 as determined by
our novel scoring system of the co-immunoprecipitation were generated using this method. The
proteins selected are PF07_0114, PF11_0154, PFF0695, PFF0625, PF11_0259, and PF11_0395.
When performing PCR to generate the DNA template, the primers had the SP6 promoter sequence,
Kozak region, and hybridization region added. After PCR and confirmation of the correctly sized
product by agarose electrophoresis, the plasmid DNA was purified using the PureYield Plasmid
Miniprep System following the manufacturer’s instructions. Next, the DNA template was used in
the translation protocol. Each gene was set up in the following reaction:
TnT SP6 High-Yield Wheat Germ Master Mix

30μl

DNA Template

5-8μl

(35S) Methionine

2-4μl

Nuclease Free Water

Bring Final Volume to 50μl

After all reagents were added and mixed, the translation reaction was incubated at 25°C for
2 hours. The success of the transcription/translation reaction was verified by running 2μl of the final
product on an SDS-PAGE gel. Once the gel was run to completion, the gel was fixed in a 50%
methanol and 7% acetic acid solution for 15 minutes. The gel was then incubated in a 7% glycerol,
7% methanol, and 7% acetic acid solution for 10 minutes. Lastly, the gel was incubated for 5
minutes in 10% glycerol. In order to dry the gel, the gel is placed on a piece of Whatman 3MM
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filter paper, wrapped in plastic wrap, and dried at 80°C for 2 hours. The dried gel was then exposed
to a phosphorimaging screen and imaged to detect the presence of the (35S) Methionine and
determine if the translation was successful.

4.2.10 Validation of the PfPK6 Interactome through Pull-Down Analysis
To validate the interactors of PfPK6 identified by co-immunoprecipitation of HA-tagged
Plasmodium falciparum lysates, we performed pull-down analysis of recombinant GST-PfPK6 and
identified interactors generated through the TnT SP6 Wheat Germ Expression System. For this
validation, we used the Pierce GST Protein Interaction Pull-Down Kit from Thermo Scientific and
followed the provided instructions with some adaptations for optimization purposes. The pull-down
validation was performed for four of the interactors listed above (PF11_0154, MAL8P1.127,
PF11_0259, and PF11_0305) with and without GST-PfPK6. Afterward the columns were labeled
and a 1:1 wash solution was prepared of TBS: Pull-down lysis buffer, 50μl of re-suspended
glutathione agarose resin slurry was added to each column using a wide bore pipette tip. The resin
was washed with 400μl of wash solution followed by centrifuging at 1,250 x g for 30 seconds. The
washes were repeated four times for a total of five washes. In order to prevent non-specific binding
of the interactors with the GST agarose resin, 3% BSA in wash solution was added to each column
and incubated for 1 hour at 4°C with end-over-end mixing. After centrifuging to remove the
blocking solution, the bait GST-PfPK6 was immobilized to the GST agarose resin by adding 25μg
of purified GST-PfPK6 in a total of 500μl of wash buffer. For the control pull-down reactions not
containing GST-PfPK6, 500μl of wash buffer was added. The GST-PfPK6 bait was incubated with
the GST agarose resin for 1 hour at 4°C and was then centrifuged as before. Next, the resin was
washed five times with 500μl of wash solution followed by centrifuging at 1,250 x g for 30
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seconds. Following the immobilization of the bait protein and thorough washing, the prey protein
was captured. A total of 10μl of the TnT reaction for each interactor was added in 500μl of wash
buffer. The prey incubated on the GST agarose resin for 6 hours at 4°C with end-over-end mixing.
After centrifuging at 1,250 x g for 30 seconds, the samples were washed ten times with 500μl of
wash solution with 50mM NaCl added. After thorough washing, the bait-prey was eluted by adding
20μl of elution buffer (10mM glutathione in TBS pH 8.0), incubating for 5 minutes with gentle
mixing, and centrifuging at 1,250 x g for 30 seconds. The pull-down samples were analyzed by
SDS-PAGE and autoradiography.

4.3 Results and Discussion
4.3.1 Our Global Phosphoproteomic Analysis Identifies Putative MAPK/CDK Substrates
The intraerythrocytic cell cycle of the malaria parasite digresses from the traditional
eukaryotic cell cycle model. The six identified Plasmodium CDK-related protein kinases [21, 112]
are likely to be the key regulators of the unique cell cycle progression. To validate this prediction
and gain insight into the physiological functions of Plasmodium CDK-related kinases, it is essential
to identify their cellular substrates. CDKs are proline-directed serine/threonine protein kinases that
have a strong requirement for basic amino acids, such as arginine and lysine, at the +3 site [126].
The global phosphoproteomics study performed in our lab resulted in the identification of 206
proline-directed serine/threonine phosphorylated proteins [1]. Further filtering was performed to
isolate phosphorylated proteins with the strong CDK consensus sequence pS/T-P-X-K/R, which
narrowed the phosphorylated proteins to 45 proteins that are putative Plasmodium CDK substrates.
Among the proteins that may be phosphorylated by Plasmodium CDKs are homologs of origin
recognition complex subunit 2 (Orc2) (MAL1P1.21), Orc4 (PF13_0189), and Orc1/CDK6
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(PFE0155w), which are all components of the pre-replication complex and are known CDK
substrates in other eukaryotes. Once mammalian Orc proteins are phosphorylated by CDKs, this
prevents helicase loading beyond G1 phase of the cell cycle and prevents re-replication [127, 128].
Among those proteins phosphorylated at the strong CDK consensus sequence are significant
proteins potentially involved in regulating the parasite’s DNA replication, transcription, or mitosis
such as homologs of cell division cycle protein 48 (PFF0940c) and regulator of chromosome
condensation (MAL7P1.38). PTMScan® Direct was utilized to further identify putative Plasmodium
CDK substrates. This technique isolates proteins with specific post-translational modifications, in
our case, proteins that are phosphorylated at the strong CDK consensus sequence. Using this
antibody-based pull-down of phospho-motif peptides in duplicate experiments, we identified a total
of 48 unique phosphorylation events. Significantly, the PTMScan® immunoprecipitation identified
two phosphorylation events, homologs of cell division cycle protein 48 (PFF0940c) (S512) and
regulator of chromosome condensation (MAL7P1.38) (S602) that were predicted MAPK/CDK
substrates from the global phosphoproteomic analysis. It would be crucial to identify which
substrates the kinase is acting on to delineate the role of PfPK6 in the Plasmodium cell cycle. Five
of the predicted CDK substrates identified by the global phosphoproteomics study or by PTMScan®
Immunoprecipitation were investigated further. These five putative substrates are listed in Table 4
along with their peak phosphorylation stage as well as the biological process and molecular
function of the phosphorylated protein.

4.3.2 Characterization of PfPK6 and Identification of Novel PfPK6 Substrates
In an attempt to further unravel PfPK6’s role in Plasmodium falciparum we performed
immunofluorescence assays to determine its subcellular localization. Stage-specific examination of
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the kinase revealed an extra-nuclear cellular localization (Fig. 25A) as evident from PfPK6 not colocalizing with the nuclear stain DAPI (Fig. 25B). Although PfPK6 is a CDK-like kinase, it is
clearly not nuclear and may function by phosphorylating proteins that are exported to and/or from
the nucleus. PfPK6 was further characterized by determining its stage-specific profile. Western blot
analysis of 8 hour time point lysates reveals little PfPK6 expression at the late ring and early
trophozoite stages, while expression reaches its peak at the late intraerythrocytic stages (Fig. 25C).
After examining the phosphoproteins with phosphorylation events occurring at the strong
CDK consensus sequence, we generated His-tagged recombinant forms of five proteins identified
through our previous global phosphoproteomics analysis or previous PTMScan®
Immunoprecipitation (Table 4). One of the chosen proteins, regulator of chromosome condensation
(MAL7P1.38) was identified through both types of analysis. To investigate the role of PfPK6 in
Plasmodium falciparum we performed in vitro kinase assays to identify substrates of this CDK-like
kinase. Fig. 26A and 26C show 1μg of recombinant PfPK6 and 5μg of substrate was used for each
assay condition. After four independent kinase assays, it was clear that PfPK6 was able to
phosphorylate putative regulator of chromosome condensation (MAL7P1.38) to a greater extent
than the control substrate histone or greater than it’s own auto-phosphorylation (Fig. 26B). PfPK6
was also able to phosphorylate RNA binding protein (PF10_0047) to a much lesser extent (Fig.
26D). The ability of PfPK6 to phosphorylate these substrates was determined by normalizing signal
intensity values to the master mix control (0%) and PfPK6 phosphorylation of histone (100%).
PfPK6 phosphorylation of MAL7P1.38 was 276%, which is much greater than PfPK6’s autophosphorylation or phosphorylation of the control histone at 100% (Fig. 26E). PfPK6’s
phosphorylation of PF10_0047 was 50% (Fig. 26E). The ability of PfPK6 to phosphorylate a
putative regulator of chromosome condensation and a RNA binding protein is suggestive of its
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nuclear function although the nuclear localization of PfPK6 is not evident. It is possible that these
substrates of PfPK6 shuttle in and out of the nucleus.

4.3.3 Key T-loop Residues Greatly Affect PfPK6 Auto-phosphorylation and Activity Towards
Substrates
PfPK6 demonstrates homology to both CDKs and MAPKs; however, molecular modeling of
PfPK6 suggests its structure is more closely related to CDKs. The regulatory phosphorylation sites,
typically found in CDKs, are conserved in PfPK6 (Thr14, Thr15, and Thr160 in CDK2); however,
PfPK6 lacks the canonical cyclin binding PSTAIRE motif, which is replaced by a SKCILRE
sequence [19]. Further evidence supporting the cyclin-independent activity of PfPK6 is the fact that
the kinase shows significant auto-phosphorylation and phosphorylation of the substrate histone in
the absence of a cyclin binding partner and PfPK6 activity is not stimulated by incubation with a
cyclin [19]. By examining the T-loop of PfPK6 and comparing it to eukaryotic CDKs, it would be
predicted that Thr173 phosphorylation is required for full activation of PfPK6. To investigate the
role of T173 of PfPK6 in its catalytic activity, we tested the property of a T173A mutant. However,
in vitro kinase assays using a T173A mutated PfPK6 resulted in no effect on PfPK6 autophosphorylation, phosphorylation of the control substrate histone, or phosphorylation of the novel
substrate MAL7P1.38 (Fig. 27A, Fig. 27B, and Fig. 27E). The fact that Thr173 phosphorylation has
no effect on PfPK6 activity suggests that this Thr residue has no role in the catalytic activity of
PfPK6 unlike CDKs. Furthermore, in MAP kinases the activation loop contains a signature TxY
motif, whereas in PfPK6 it is TxT. Our results thus supports the notion that PfPK6 is a unique
“cyclin-independent” CDK.

122

Because there are two additional Thr residues adjacent to Thr173, we investigated the role
of Thr175 and Thr178 by mutating them to Ala. Both of these threonine residues are also located in
the T-loop and may have an effect on PfPK6’s phosphorylation. The in vitro kinase assays revealed
the T175A mutation had no effect on PfPK6 auto-phosphorylation or substrate phosphorylation. In
fact, the mutation of Thr175 to an alanine increased its activity. PfPK6 phosphorylation of the
control histone by T175A was 127% compared to the 100% of histone phosphorylation in the wild
type, and was 162% for the novel substrate MAL7P1.38 (Fig. 27E). The absence of an effect in
PfPK6 activity when Thr175 is mutated suggests similar to Thr173, this residue has no influence on
the catalytic function of PfPK6. Next, we investigated the role of Thr178 residue within the T-loop
for its significance in PfPK6 auto-phosphorylation or substrate phosphorylation. When Thr178 was
mutated to an alanine residue, PfPK6 exhibited a total loss of both auto-phosphorylation and
substrate phosphorylation (Fig. 27C, Fig. 27D, and Fig. 27E). This result suggests that Thr178 is
crucial for both auto-phosphorylation and substrate phosphorylation. The phospho-mimic mutants
T178D or T178E were unable to restore PfPK6 activity (Fig. 27C, 27D, and 27E). Overall the sitedirected mutagenesis showed the significance of phosphorylation at Thr178 in leading to full
activation of PfPK6, while Thr173 and Thr175 phosphorylation had no effect on activity.

4.3.4 Co-Immunoprecipitation Identifies the Interactome of PfPK6 and Pfmrk
In addition to identifying substrates, the role a protein kinase plays can be determined by
detecting interacting partners. To identify substrate/interactors of Plasmodium CDK-like kinases,
we used HA-tagged PfPK6 and Pfmrk lines where endogenous protein kinase loci were replaced
with epitope-tagged genes by homologous recombination. Western blot analysis using an anti-HA
antibody confirmed the presence of the HA-tag in both the PfPK6 and Pfmrk cell lines and the
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absence of HA in the 3D7 wild type control (Fig. 28A). After confirming the presence of the HAtagged kinases in their respective cell lines, co-immunoprecipitation was performed with HAtagged PfPK6 and Pfmrk as baits with highly specific anti-HA antibody cross-linked to agarose
beads, followed by mass spectrometric analyses of tryptic peptides (Fig. 28B-28D). The coimmunoprecipitation identified the components of the protein interaction complexes of these
kinases. Non-specific interactions were eliminated through the use of a novel filtering system
based on Shannon entropy and the number of spectral counts observed in a pair of replicates. The
validity of our scoring system is underscored by the identification of Pfcyc-1 and PfMAT1 as
specific interactors of Pfmrk, which have been previously reported. Our analyses of HA-PfPK6 and
HA-Pfmrk immunoprecipitates have identified 15 and 21 proteins in the interaction complex,
respectively. The top interactors of Pfmrk are listed in Table 5A, while the top interactors of PfPK6
are listed in Table 5B. Interestingly, all of the proteins identified as interactors of either PfPK6 or
Pfmrk were only found as interactors of that particular kinase. There was no crossover of identified
interactors between the co-immunoprecipitation experiments. Among the proteins identified in the
PfPK6 interaction complex are many with nuclear roles e.g. Nucleolar GTP-binding protein 1
(PFF0625w) and an uncharacterized protein (PFF0695w) with a role in mRNA processing and
RNA splicing. Components of the Prmrk interaction complex appear to contain proteins with
diverse functions such as a DNA excision-repair helicase homolog (PFI1650w) and a
methyltransferase (PF07_0015).
In an effort to validate the interactors identified by mass spectrometry of the
immunoprecipitated complex of HA-PfPK6 we tested binary interactions between GST-PfPK6 as
the bait and the interactors identified above as the prey. The TnT SP6 wheat germ protein
expression system was used to produce the previously identified radiolabeled interactors of PfPK6
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(PF11_0154, MAL8P1.127, PFF0625w, PF11_0259, and PF11_0305) (Fig. 29A). We were
successful in expressing four of the interactors. GST-PfPK6 was immobilized to anti-GST agarose
beads followed by incubation with the interactors. The pull-down analysis confirmed the interaction
of PfPK6 with these four proteins (Fig. 29B). When comparing the amount of protein pulled-down
in the presence and absence of PfPK6, it is clear that PfPK6 does indeed interact with these proteins
as is evident by the enrichment of prey protein when PfPK6 was included (Fig. 29C). We used the
identified interactors and substrates of PfPK6 in this study as well as previously established
interactors published on PlasmoDB to map the preliminary interactome of PfPK6 (Fig. 30)

4.4 Conclusions
The malaria parasite, Plasmodium falciparum, undergoes complex developmental cycles in
its human and insect hosts, which involves fluctuations between stages of intense cell proliferation
and stages of withdrawal from proliferation. In traditional eukaryotic cells, members of the cyclindependent kinase family as well as other protein kinases regulate progression of the cell cycle,
which is expected to be the case for Plasmodium cell division as well. Several CDK homologues,
e.g. PfPK5, PfPK6, and Pfmrk, have been identified in Plasmodium falciparum [19]. Of these
CDK-like malaria parasite kinases, PfPK6 possesses novel features: (a) it exhibits significant
homology to MAP kinases although the PfPK6 molecular model shows structural similarity to the
CDKs; (b) the canonical PSTAIRE cyclin binding motif is changed to SKCILRE in PfPK6; (c) the
recombinant protein shows robust auto-phosphorylation activity and unlike PfPK5 and Pfmrk,
PfPK6 activity is not stimulated by any cyclin; (d) similar to tyrosine kinases, PfPK6 prefers Mn2+
over Mg2+ as the divalent cation; and (e) the sensitivity of PfPK6 to the CDK inhibitor roscovitine
is more analogous to MAP kinases rather than CDK1, CDK2, or CDK5 [19, 37].
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To gain a better understanding of the cellular function of this atypical CDK-like kinase, we
investigated the substrates and interactors of PfPK6. This study utilized our phosphoproteomic
dataset and PTMScan® Direct to identify putative CDK/MAPK Plasmodium substrates; and it
revealed the ability of PfPK6 to directly phosphorylate putative regulator of chromosome
condensation (MAL7P1.38) and RNA binding protein (PF10_0047). The putative regulator of
chromosome condensation MAL7P1.38 has approximately 50% similarity to the regulator of
chromosome condensation RCC1. The RCC1 protein functions as a RAN GTPase activating
protein and is involved in mitotic spindle assembly, nuclear envelope formation, and
nucleocytoplasmic transport [149]. The RNA binding protein PF10_0047 is a homologue of serinearginine (SR) rich proteins involved in pre-mRNA splicing and are known to be involved in
nucleocytoplasmic transport, thus PfPK6 can phosphorylate these proteins while localized in the
cytoplasm.
In addition to identifying substrates, we used co-immunoprecipitation of HA-PfPK6 with a
novel stringent scoring system to detect the interacting partners of PfPK6. Among the proteins
identified in the PfPK6 interaction complex are many with nuclear roles e.g. Nucleolar GTPbinding protein 1 (PFF0625w) and an uncharacterized protein (PFF0695w) with a role in mRNA
processing and RNA splicing. Therefore, the identification of these proteins through coimmunoprecipitation studies also supports the role of PfPK6 in nuclear function. Additionally, the
data from our study has enabled us to construct a preliminary interactome of the kinase, shedding
light on one of the many signaling pathways of the Plasmodium cell cycle. This is the first
interactome developed for any of the protein kinases of Plasmodium.
Our study also defined the catalytic mechanism of PfPK6 through specification of the amino
acid residue involved in auto-phosphorylation. This analysis highlights the importance of T178 in
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the T-loop of PfPK6 for catalytic activity and substrate phosphorylation. It is to be noted that
phosphomimic residues, glutamate or aspartate, did not rescue PfPK6 activity. Our previous
molecular modeling [19] suggests that the Thr178 residue hydrogen bonds to Asp143 in the
catalytic loop. However, the mutants T178A, T178E, and T178D were not able to do so.
In conclusion, this study has made significant progress in defining catalytic mechanism and
the cellular role(s) of PfPK6.
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Figure 24: PfPK6 Localization and Expression Pattern
(A) Immunofluorescence assay depicting the cellular localization of PfPK6 in green and nuclear
localization in blue. Cellular localization of PfPK6 at the ring, trophozoite, schizont, and segmenter
stages were all examined. (B) Immunofluorescence assay illustrating the extra-nuclear localization
of PfPK6. PfPK6 does not co-localization with the DAPI nuclear stain. (C) Stage-specific profile of
PfPK6 expression determined from western blot analysis of 8 hour 3D7 lysate time points.
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Table 4: Identification of Putative Plasmodium CDK Substrates
Annotation

PlasmoDB
ID

Phosphorylated
Peptide

Regulator of
Chromosome
MAL7P1.38 SYLSNESPTRKQP
Condensation,
putative
Conserved
Plasmodium
PFE0155w PKQYYESPFKVLY
protein
Conserved
Plasmodium PF11_0332 ELTKRGSPEGLAK
protein
RNA Binding
Protein,
PF10_0047 GGDENISLKNYKN
putative

Site
Position
602

Biological
Process
Cell Cycle
and
Chromosome
Condensation

Molecular
Function

Peak Protein
Expression

Peak
Phosphorylation

Chromatin
Binding

Global

Schizont

730

DNA
Replication

ATP Binding

Ring

Schizont

33

Unclassified

Nucleic Acid
Binding

N/A

N/A

685

Unclassified

Nucleic Acid
Binding

Ring/Trophozoite

Trophozoite/Schizont

Ring/Schizont

N/A

Ring/Schizont

N/A

DNA-Directed
RNA
Polymerase II,
putative

PFC0805w

PAYILQSPVQIKQ

2410

Transcription
from RNA
polymerase II
promoter

DNA-Directed
RNA
Polymerase II,
putative

PFC0805w

NAHQPMSPAYILQ

2403

Transcription
from RNA
polymerase II
promoter

DNA Binding,
DNA-Directed
RNA
Polymerase
Activity,
Protein Binding
DNA Binding,
DNA-Directed
RNA
Polymerase
Activity,
Protein Binding

Five proteins that are predicted Plasmodium CDK substrates were selected for further investigation
to determine the ability of PfPK6 to phosphorylate them. The table lists the chosen proteins as well
as the detected phosphorylation event occurring at the strong CDK consensus sequence, the site
position of the phosphorylation event, the biological process and molecular function of the
phosphorylated protein as determined by GO term analysis, and the peak protein expression and
phosphorylation stage as revealed in our global phosphoproteomic analysis [1].
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Figure 25: Identification of Novel Substrates of PfPK6
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(A) Coomasie blue stained gel of the in vitro kinase assays. Lane 1: Master mix, Lane 2: Histone,
Lane 3: PfPK6, Lane 4: PfPK6 + Histone, Lane 5: MAL7P1.38, Lane 6: PfPK6 + MAL7P1.38,
Lane 7: PFE0155w, Lane 8: PfPK6 + PFE0155w. (B) Phosphoimage of the in vitro kinase assay gel
depicted in (A). (C) Coomassie blue stained gel of the in vitro kinase assays. Lane 1: PF11_0332,
Lane 2: PfPK6 + PF11_0332, Lane 3: PF10_0047, Lane 4: PfPK6 + PF10_0047. (D)
Phosphoimage of the in vitro kinase assay gel depicted in (C). (E) Normalized signal intensity
values. Master mix alone was set as the 0% value and PfPK6 auto-phosphorylation was set as the
100% value.
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Figure 26: Key T-loop Residues Greatly Affect PfPK6 Auto-Phosphorylation and Activity
Towards Substrates
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(A) Coomasie blue stained gel of the in vitro kinase assays. Lane 1: Master mix, Lane 2: Histone,
Lane 3: MAL7P1.38, Lane 4: PfPK6 wild type (WT), Lane 5: PfPK6 WT + Histone, Lane 6: PfPK6
WT + MAL7P1.38, Lane 7: PfPK6 T173A, Lane 8: PfPK6 T173A + Histone, Lane 9: PfPK6
T173A + MAL7P1.38. (B) Phosphoimage of the in vitro kinase assay gel depicted in (A). (C)
Coomassie blue stained gel of the in vitro kinase assays. Lane 1: PfPK6 T175A, Lane 2: PfPK6
T175A + Histone, Lane 3: PfPK6 T175A + MAL7P1.38, Lane 4: PfPK6 T178D, Lane 5: PfPK6
T178D + Histone, Lane 6: PfPK6 T178D + MAL7P1.38, Lane 7: PfPK6 T178E, Lane 8: PfPK6
T178E + Histone, Lane 9: PfPK6 T178E + MAL7P1.38. (D) Phosphoimage of the in vitro kinase
assay gel depicted in (C). (E) Normalized signal intensity values. Master mix alone was set as the
0% value and PfPK6 auto-phosphorylation was set as the 100% value.
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Table 5: Identification of the (A) Pfmrk and (B) PfPK6 Interactomes
Table 5A: Identification of the Pfmrk Interactome
Gene
PFE0610c

Description
CDK-activating kinase assembly factor,
putative

mrkE

mrkWT

pk6Int

Ratio E /WT

0.999

0.078

0

12.78

PFI1650w

DNA excision-repair helicase, putative

0.989

0.110

0

8.94

PF10_0141

Cdk7, putative

0.943

0.156

0

6.02

PF14_0605

Cyclin homologue

0.811

0.139

0

5.82

PF07_0015

Methyltransferase, putative

0.994

0.20

0

4.79

PFF0765c

Uncharacterized protein

0.968

0.242

0

3.99

PF14_0618

Putative uncharacterized protein

0.811

0.258

0

3.14

Table 5B: Identification of the PfPK6 Interactome

The top interactors identified in the HA-tagged co-immunoprecipitation are listed. (A) The top
seven interactors of Pfmrk including PFE0610c and PF14_0605 that are previously demonstrated
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interactors of Pfmrk. The mrkE column shows the normalized spectral count for a particular protein
in the HA-Pfmrk cell line, while the mrkWT column shows the normalized spectral count for the
same protein in the wild type 3D7 cell line. The next column, pk6Int, indicates whether a protein
was considered to be an interactor for PfPK6 as well as Pfmrk. Finally, the Ratio E/WT column
calculates how enriched a particular protein was in the HA-Pfmrk cell line compared to the wild
type 3D7 cell line. For this particular column, the higher the value, the stronger the interaction
between the specific protein and Pfmrk. (B) The top eight interactors of PfPK6 as revealed after the
co-immunoprecipitation. The mrkE column indicates whether a protein was considered to be an
interactor for Pfmrk as well as PfPK6. The Pk6E column shows the normalized spectral count for a
particular protein in the HA-PfPK6 cell line, while the PK6WTE column shows the normalized
spectral count for the same protein in the wild type 3D7 cell line. The next column, the Ratio of E
to WT column calculates how enriched a particular protein was in the HA-Pfmrk cell line compared
to the wild type 3D7 cell line.
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Figure 27: Identification of the PfPK6 Interactome
(A) Western blot analysis showing the absence of the HA tag in the 3D7 wild type control cell line
and the presence of the HA-tagged proteins in either the HA-tagged PfPK6 or HA-tagged Pfmrk
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cell lines. (B) Silver stained SDS-Page image showing 10% of the final elution from the 3D7 wild
type control co-immunoprecipitation. (C) Silver stained SDS-Page image showing 10% of the final
elution from the HA-tagged PfPK6 co-immunoprecipitation. (D) Silver stained SDS-Page image
showing 10% of the final elution from the HA-tagged Pfmrk co-immunoprecipitation.
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Figure 28: Verification of the PfPK6 Interactome
Pull-down analysis using GST-PfPK6 was used to confirm the interactions identified through coimmunoprecipitation. (A) Phoshoimage displaying the PfPK6 interactors generated with the TnT
SP6 Wheat Germ Expression System. (B) Phosphoimage showing the ability of GST-PfPK6 to
pull-down the interactors identified in the co-immunoprecipitation experiment. (C) Histogram
depicting the extent of interaction of PfPK6 with the proteins identified in the coimmunoprecipitation.
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Figure 29: Preliminary Interaction Network of PfPK6
The interactors of PfPK6 identified in this study as well as previously identified interactors were
mapped to reveal the PfPK6 preliminary interactome. The Plasmodium proteins in blue are the
interactors of PfPK6 identified through HA-tagged co-immunoprecipitation and confirmed by pulldown analysis. The proteins in green were top PfPK6 interactors as revealed through HA-tagged
co-immunoprecipitation, but have yet to be confirmed through pull-down analysis. Proteins in
orange are previously published substrates of PfPK6. The yellow protein was a novel substrate of
PfPK6 classified in this study. All of the red proteins were proven interactors of their respective
proteins through yeast-two hybrid experiments published on PlasmoDB.
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CHAPTER 5: GENERAL DISCUSSIONS AND CONCLUSIONS
The aim of this work was to investigate the signaling mechanisms that regulate
intraerythrocytic progression of Plasmodium falciparum. Because reversible phosphorylation plays
a key role in intracellular signaling we focused on the role of protein kinases in the atypical
intraerythrocytic life cycle. We defined the constitutive and regulated expression of the Plasmodium
proteome during the intraerythrocytic developmental cycle, which provided insight into the
dynamics of phosphorylation during asexual cycle progression. We identified 2,767 proteins, 1,337
phosphoproteins, and 6,293 phosphorylation sites through quantitative phosphoproteomics analyses
and tracked their individual changes in expression and/or phosphorylation as the malaria parasite
progressed from one intraerythrocytic stage to the next. We showed that 34% of identified proteins
and 75% of phosphorylation sites are dynamic and exhibit changes in abundance as the
intraerythrocytic cycle progresses. This study is the most comprehensive and the only quantitative
phosphoproteomic analyses to date examining progression through the entire intraerythrocytic cell
cycle, marking a tremendous step forward in delineating the molecular mechanisms governing the
Plasmodium intraerythrocytic cell cycle.
Our success with comprehensive quantitative phosphoproteomics analyses, prompted us to
apply this approach to delineate the signaling network where one of the orphan Plasmodium
kinases, PfPK7, functions. For this analysis we compared the phosphoproteome profiles of the wild
type P. falciparum 3D7 and the pfpk7 knockout lines. In the absence of a reliable conditional knock
out system, generating kinase knockout cell lines in the haploid genome of the Plasmodium
intraerythrocytic cell cycle stages is particularly challenging. Fortunately, the knock out of pfpk7 is
not lethal, and exhibits a phenotype of a slower growth rate as a result of reduced number of
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merozoites per schizont [27]. Since PfPK7 has a known effect in Plasmodium and is a non-essential
gene, we were able to use quantitative phosphoproteomics on a PfPK7- cell line and compare it to
the wild type 3D7 cell line to reveal the potential substrates of this atypical kinase. This analysis
identified 146 putative PfPK7 substrates; three of these were proven to be direct substrates of the
kinase, while multiple were not directly phosphorylated. This suggests that PfPK7 may function as
an upstream regulatory kinase, acting on down-stream protein kinases, which may lead to the
decreased phosphorylation of the 146 proteins observed in this study. This was the first use of
quantitative phosphoproteomic analyses to identify substrates of a protein kinase, which may now
be used to investigate the role of other protein kinases within Plasmodium.
Finally, this dissertation focused on elucidating the function of the atypical CDK-like
kinase PfPK6 through characterization of its substrates and interactors. Our phosphoproteomic
dataset was analyzed for phosphorylation events occurring at the stringent CDK phosphorylation
motif in order to identify putative CDK substrates. The ability of PfPK6 to phosphorylate these
putative substrates was tested and resulted in the identification of two novel PfPK6 substrates. We
also uncovered the preliminary PfPK6 interactome by detecting the direct interacting partners of
PfPK6. A summation of our findings is discussed below in the context of their relevance and
significance to our understanding of the molecular operations regulating the Plasmodium
falciparum cell cycle.

5.1 The Plasmodium falciparum Proteome and Phosphoproteome
Plasmodium falciparum exhibits an unusual asexual intraerythrocytic cell cycle, which
diverges from the traditional paradigm of cell cycle typically seen in eukaryotes. Specifically, P.
falciparum undergoes multiple distinct rounds of DNA replication and nuclear division without
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cytokinesis. Gaining a better understanding of the molecular instruments coordinating the multitude
of events that progress the parasite through the intraerythrocytic developmental stages is of
fundamental importance for rational design of novel intervention strategies.
To date, there have been no reports on the analysis of the dynamics of protein expression
and phosphorylation during the entire intraerythrocytic developmental cycle of Plasmodium. In this
study, we present the most comprehensive analysis of protein expression and phosphorylation
across the three major developmental stages in the P. falciparum intraerythrocytic asexual cycle
using isobaric tagging for relative and absolute quantitation [58, 87]. We identified 2,767 proteins,
1,337 phosphoproteins, and 6,293 phosphorylation sites from the ring, trophozoite, and schizont
stages, the three major stages in the asexual cycle of malaria parasites in red blood cells (for more
information on the Plasmodium life cycle, see reference [150]). This comparative analysis revealed
stage-specific profiles of protein expression and phosphorylation. A wealth of insight is contained
within these quantitative profiles of P. falciparum protein and phosphoprotein expression.
Importantly, the 2,914 unique proteins detected in these proteomic and phosphoproteomic analyses
comprise approximately 55% of the current proteome prediction [20]. Since many proteins of the
Plasmodium proteome are exclusively expressed in the mosquito stages, as reported earlier [84, 85]
and many others are restricted to liver and gametocyte stages during infection of the human host,
we propose that our present dataset likely encompasses the majority of intraerythrocytic stagespecific proteins. This data obtained in our study have significantly enhanced numbers of
Plasmodium protein identifications compared to previous proteomics reports [83, 91]. The greater
depth of our analysis compared to previous attempts reflects multiple factors. First, by
simultaneously surveying all intraerythrocytic developmental stages, each with its own protein
complement, our study can encompass a larger fraction of the proteomic landscape. Second, the
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continuous improvements in instrument sensitivity and methodology resulted in increased number
of protein and phosphorylation identifications than that are typically obtained via proteomics
analysis [92].
An intriguing aspect of intraerythrocytic differentiation of Plasmodium is the mechanism by
which parasites regulate gene expression. Based on transcriptome analysis, it was initially believed
that the majority of genes are globally controlled in a stage-dependent manner [105, 106], although
it is now generally accepted that post-transcriptional and post-translational regulatory mechanisms
have more dominant roles in regulation of intraerythrocytic gene expression [79, 80]. Our study
supports the idea that post-transcriptional regulation of gene expression plays a major role in
Plasmodium. Our analysis revealed that over 60% of all identified proteins are constitutively
expressed at relatively constant amounts during all three intraerythrocytic stages.
Another interesting aspect of our phosphoproteome analysis is the discovery of tyrosine
phosphorylation of a large number of Plasmodium proteins in the absence of true tyrosine kinase
homologues. This underscores the importance of dual-specificity kinases in the parasite or the role
of host cell tyrosine kinase. Our study also revealed that peak protein expression and
phosphorylation are unlinked.
This research also identified 43 distinct phosphorylation motifs and a range of potential
MAPK/CDK substrates. Among the proteins that may be phosphorylated by Plasmodium CDKs are
homologs of origin recognition complex subunit 2 (Orc2) (MAL7P1.21), Orc4 (PF13_0189), and
Orc1/CDC6 (PFE0155w), components of the pre-replication complex that are known CDK
substrates in other eukaryotes. Additional pre-replicative complex proteins that are phosphorylated
at the weak CDK consensus motif (pS/T-P) are MCM4, and MCM5. Mammalian ORC and MCM
subunits are phosphorylated by CDKs to prevent helicase loading beyond G1 phase of the cell
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cycle, thus preventing re-replication [127, 128]. Other proteins of significance in potentially
regulating the parasite’s DNA replication, transcription, or mitosis that are phosphorylated at the
strong CDK motif are homologs of cell division cycle protein 48 (PFF0940c) and regulator of
chromosome condensation (MAL7P1.38). Closer examination of phosphorylation events identified
30 protein kinases with 126 phosphorylation sites within the kinase domain or in N- or C-terminal
tails. Many of these phosphorylation events are likely CK2-mediated. Through this global
phosphoproteomics analyses we defined the constitutive and regulated expression of the
Plasmodium proteome during intraerythrocytic development, offering an insight into the dynamics
of phosphorylation during asexual cycle progression. Our system-wide comprehensive approach is
a major step toward defining kinase-substrate pairs operative in various signaling networks in the
parasite.
A major challenge in the post-genome sequencing era is to understand the cellular roles of
the vast number of proteins whose function is not deducible from sequence analysis. Achieving a
comprehensive functional understanding of the Plasmodium falciparum proteome is particularly
challenging, given that 60% of putative proteins are Plasmodium-specific proteins that have no
known orthologs in other organisms. This work brings significant contribution to the ongoing
global efforts at implementing functional genomics studies of Plasmodium falciparum, the end goal
of which is to facilitate the discovery of novel interference drug targets. Our global
phosphoproteomic analysis is the only quantitative study that compares dynamics of
phosphorylation events as the parasite progresses through its asexual developmental stages in the
host erythrocyte. Our study also represents a step toward elucidation of the kinase-substrate pairs
that will eventually form the basis of a comprehensive Plasmodium signaling network.
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5.2 The Use of Kinase Negative Phosphoproteomics to Delineate the Role of A Protein Kinase
in Plasmodium
We demonstrated for the first time that phosphoproteomic analysis can be applied to a
kinase negative cell line in order to detect novel substrates and shed light on the role a protein
kinase plays in Plasmodium falciparum signaling pathways. A major challenge in understanding the
unique nature of the P. falciparum cell cycle is the lack of information currently known about
malaria signaling cascades. Thorough investigation of the molecular operators governing the
intraerythrocytic cell cycle progression is needed. Furthermore, characterization of the protein
kinases and respective substrates involved in this process are of utmost importance. Because of the
novelty of Plasmodium protein kinases they could be considered to be ideal novel therapeutic
targets. One atypical Plasmodium protein kinase is PfPK7, which possesses hybrid features and
does not show strong homology to eukaryotic protein kinases.
This kinase negative phosphoproteomic study identified 146 putative substrates of PfPK7 as
well as three phosphorylation motifs enriched among Plasmodium proteins that are down regulated
in the absence of PfPK7. We were able to verify the ability of PfPK7 to directly utilize three of the
putative substrates identified in the kinase negative phosphoproteomic analysis. However, PfPK7
did not utilize all of the potential substrates identified in this study, suggesting the role of PfPK7 as
an upstream regulatory kinase. Our study provides the foundation for the use of quantitative
phosphoproteomic analysis of kinase negative mutants in order to delineate their function and role
in parasite signaling networks. This work represents a substantial advancement toward defining
kinase-substrate interactions by unveiling the preliminary role of PfPK7 in Plasmodium signaling
networks. Further studies will determine whether PfPK7 acts as an upstream regulatory kinase.
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5.3 Elucidating the Function of Plasmodium falciparum Protein Kinases Through
Substrate/Interactor Characterization
The intraerythrocytic development of the malaria parasite diverges from the eukaryotic cell
cycle paradigm that has emerged largely from studies in yeast cells. In the typical eukaryotic cell
cycle, chromosomes replicate only once and the transition of one cell cycle stage to the next is
associated with the oscillation of CDK activity. Likewise, it is expected that proteins belonging to
the CDK-related subfamily will be key regulators in the unique Plasmodium intraerythrocytic
developmental cycle. Six CDK-related protein kinases have been identified in P. falciparum [19,
21]. To gain an insight into physiological functions of Plasmodium CDK-related kinases it is
necessary to identify their cellular substrates and interactors. However, defining kinase-substrate
pairs is one of the most challenging aspects of kinomics.
Our research made significant progress in elucidating the function of the atypical CDK-like
kinase PfPK6. In order to identify putative CDK substrates, our phosphoproteomic dataset was
analyzed for phosphorylation events occurring at the stringent CDK phosphorylation motif.
Furthermore, PTMScan® Direct was used to identify additional CDK substrates. Following
identification of potential CDK substrates, we showed the ability of PfPK6 to directly
phosphorylate two of these novel substrates. We also uncovered the preliminary interaction network
of PfPK6 by detecting the direct interacting partners of PfPK6 through co-immunoprecipitation of
HA-tagged PfPK6. Our findings with PfPK6 are in agreement with the CDK-like nature of PfPK6
and also established a hitherto previously undefined interactome of PfPK6, while pointing toward
PfPK6 having a role in nuclear function.
In conclusion, the data presented in this dissertation 1) defined the constitutive and regulated
expression of the proteome during the intraerythrocytic developmental cycle, 2) demonstrated that

146

fluctuation and reversible phosphorylation is important for the regulation of P. falciparum’s unique
cell cycle, 3) provided the foundation for quantitative phosphoproteomic analysis of kinase negative
mutants to understand their function, 4) generated a preliminary network of interactions for PfPK6,
and 5) set the stage for defining kinase-substrate pairs that are key in various signaling networks in
the parasite and from this, perhaps the identification of novel therapeutic targets against malaria
parasites.
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